



Curriculum vitae Europass

Informații personale

Nume / Prenume	Mircea-Ioan Popa
Adresă	Aleea Târgu Neamț nr. 1, scara F, ap. 51, 062063, București, România
Telefon	(+40)0744386245
E-mail	mircea.ioan.popa@gmail.com
Naționalitate	Română
Data nașterii	1. 01.1961

Experiența profesională

Perioada	2019.01 – 2019.04
Funcția sau postul ocupat	Președinte al Consiliului Științific al INCDMM „Cantacuzino”
Activități și responsabilități principale	Potrivit Regulamentului de Organizare și Funcționare
Numele și adresa angajatorului	INCDMM „Cantacuzino”, Splaiul Independenței nr. 103, www.cantacuzino.ro
Tipul activității sau sectorul de activitate	Îndeplinirea activităților din regulamentul de funcționare al Consiliului Științific
	2018 - 2019
	Director științific al INCDMM „Cantacuzino”
	INCDMM „Cantacuzino”, Splaiul Independenței nr. 103, www.cantacuzino.ro
	2017 - 2018
	Director general al INCDMI „Cantacuzino” (apoi INCDMM „Cantacuzino”)
	INCDMM „Cantacuzino”, Splaiul Independenței nr. 103, www.cantacuzino.ro
	2012 - 2018
	Redactor șef „Infecțio.ro”
	Ridicarea nivelului revistei în clasificarea CNCS, indexarea BDI a revistei (EBSCO, ProQuest)
	Versa PULS MEDIA, Calea Rahovei 266-268, www.pulsmedia.eu
	Educație medicală continuă
	2017-2018
	Redactor șef „Romanian Archives of Microbiology and Immunology”
	Ridicarea nivelului revistei, indexarea BDI a revistei (EBSCO, ProQuest)
	Institutul Cantacuzino, Splaiul Independenței 103, www.cantacuzino.ro
	Educație medicală continuă
	2006 -
	Profesor universitar, Microbiologie
	Potrivit fișei postului
	Activități medicale, predare, cercetare, publicații medicale (din 2009 conducere de doctorat)
	UMF „Carol Davila” București, Str. Dionisie Lupu nr. 37, www.umfcd.ro
	2005-2009
	Coordonator tehnic HIV&TB, Unitatea de Management al Proiectului Fondului Global
	Potrivit fișei postului
	Ministerul Sănătății, UMP-FG, Intrarea Cristian Popișteanu nr. 1-3, www.ms.ro
	Supraveghere, monitorizare și evaluare
	2004
	Consultant în programul PHARE de întărire a sistemului de supraveghere al bolilor transmisibile pe probleme de laborator (microbiologie)
	Ministerul Sănătății, UMP-FG, Intrarea Cristian Popișteanu nr. 1-3, www.ms.ro
	Monitorizare, evaluare, organizarea de cursuri pentru personalul de specialitate din direcțiile de sănătate publică

Educație și formare

Perioada

Calificarea / diploma obținută

Disciplinele principale studiate

Numele și tipul instituției de învățământ /
furnizorului de formare

2002-2003

Consultant al Organizației Mondiale a Sănătății (OMS) pentru probleme de laborator și siguranța sângelui transfuzat, în **Afganistan**

Organizația Mondială a Sănătății, EMRO, Cairo, www.emro.who.int

Monitorizare, evaluare, supraveghere, organizare și predare cursuri, organizarea laboratorului central din **Kabul**, organizarea activității în banca centrală de sânge

1999-2006

Conferențiar universitar, Microbiologie

Potrivit fișei postului

Activități medicale, predare, cercetare, publicații medicale

UMF „Carol Davila” București, Str. Dionisie Lupu nr. 37, www.umfcd.ro

1995-1999

Șef lucrări universitar, Microbiologie

Potrivit fișei postului

Activități de organizare a lucrărilor practice, predare, cercetare, publicații medicale

UMF „Carol Davila” București, Str. Dionisie Lupu nr. 37, www.umfcd.ro

1991-1995

Asistent universitar, Microbiologie

Potrivit fișei postului

Activități de organizare a lucrărilor practice, lucrări practice, cercetare, publicații medicale

UMF „Carol Davila” București, Str. Dionisie Lupu nr. 37, www.umfcd.ro

2000-2001

Master în Managementul Serviciilor Sociale și de Sănătate

Sănătate publică, științe sociale, epidemiologie, asistență socială

Universitatea din București, Facultatea de Sociologie și Asistență Socială, www.sas.unibuc.ro

2001

Atestat de absolvire a **EPIET** (European Programme for Intervention Epidemiology) Introductory Course

Curs intensiv (3 săptămâni), epidemiologie, sănătate publică, microbiologie pentru sănătatea publică
Comisia Europeană (actualmente cursul este coordonat de ECDC, Stockholm,
www.ecdc.europa.eu)

2000

Competență în Strategii preventive

Sănătate publică, supravegherea bolilor, monitorizare și evaluare, intervenții preventive

Ministerul Sănătății, www.ms.ro; UMF „Carol Davila”, www.umfcd.ro

1999

Atestat (certificat internațional) de absolvire a Applied Epidemiology Introductory Course

Curs intensiv (4 săptămâni), epidemiologie, sănătate publică, biostatistică

Centrul de Prevenire și Control al Bolilor, **CDC**, Atlanta, USA, www.cdc.gov; Emory University, Atlanta, USA, www.emory.edu

1999

Atestat de absolvire a cursurilor și atelierelor de lucru „Le marketing social” și „Evidence-based medicine: un nouveau paradigme pour la gestion des services de santé”

Curs intensiv (2 săptămâni), sănătate publică, marketing social, medicina bazată pe dovezi

Université d'été en Administration et Gestion des Services Sanitaires, Centro Seminariale Monte Verita, Ascona, Suisse; Université de Montréal, Département d'administration de la sante

1993-1998

Titlul de Doctor în Medicină

Microbiologie, Boli infecțioase, Epidemiologie, Imunologie

Titlul tezei de doctorat: Infecții cu mycobacterii tipice și atipice în Sindromul de Imunodeficiență dobândită și în alte stări de imunodepresie. Considerații clinice, epidemiologice și de laborator;

Coordonator științific Prof. Dr. Mihai Zamfirescu, Secretar general al Academiei de Științe Medicale

1994-1999

Aptitudini și competențe personale

Limba maternă

Română

Limbi străine cunoscute

Autoevaluare

Nivel european (*)

Limba engleză

Limba franceză

Înțelegere				Vorbire				Scriere	
Ascultare		Citire		Participare la conversație		Discurs oral		Exprimare scrisă	
C1		C2		C1		C1		C1	
C1		C1		C1		C1		C1	

(*) [Nivelul Cadrului European Comun de Referință Pentru Limbi Străine](#)

Competențe și abilități sociale

Spirit de echipă (dobândit de-a lungul întregii cariere, ca elev, student, coordonator de programe studentești, medic stagiar, asistent universitar benevol (3,5 ani), parcurgând toate etapele dezvoltării carierei universitare, atât ca membru în numeroase echipe cât și în calitate de coordonator în structuri universitare, în ministerul sănătății, ca redactor șef al Infectio.ro, ca redactor șef al Rom. Archives Microbiol. Immunol., în Institutul Cantacuzino, național și internațional);

Capacitate de adaptare la medii multiculturale, obținută prin experiența de muncă în străinătate sau împreună cu diferiți colegi din străinătate, în România (expert, consultant tehnic pentru UNDP, PHARE, OMS-EURO, OMS-EMRO, HIVERA-PC7, CDC, ECDC; Chișinău, Kabul, Herat, Kandahar, Copenhaga, Geneva, Atlanta, Stockholm, Paris, Barcelona, Milano etc).

Foarte bună capacitate de comunicare, obținută ca urmare a experienței ca: membru al comunității universitare (am susținut peste 585 comunicări în diferite întruniri, sute de cursuri și lucrări practice); director, director general în ministerul sănătății (am susținut peste 200 comunicate de presă); coordonator al unei unități de management al proiectului UMF-FG, director al UMP-BM, director general și director științific în INCDMMI „Cantacuzino” cu numele actual INCDMM „Cantacuzino” etc. Am activat ca voluntar și continui să sprijin și în prezent organizații non-guvernamentale cu profil social. Am desfășurat o largă activitate de voluntariat în și pentru Institutul Cantacuzino.

Competențe și aptitudini organizatorice

În momentul de față coordonez direct o echipă formată din 12 persoane (cadre titulare, cadre asociate, cadre angajate pe perioadă determinată), disciplina microbiologie II, facultatea de medicină, UMF „Carol Davila”. Am coordonat 430 persoane în Institutul Cantacuzino, ulterior am coordonat peste 120 persoane (departamentul de cercetare, departamentul CNEIMPEM), INCDMM „Cantacuzino”. Coordonez și activitatea a 6 doctoranzi;

Am coordonat toată activitatea de sănătate publică din România în calitate de director și ulterior în calitate de director general, în ministerul sănătății.

Competențe și aptitudini de utilizare a calculatorului

Permis de conducere

Informații suplimentare

Am coordonat (cu succes) supravegherea și controlul în mai multe epidemii și izbucniri epidemice. Am coordonat și coordonez proiecte de cercetare și cercetare-dezvoltare, inclusiv în colaborare cu instituții internaționale (OMS-EURO, OMS-EMRO, CDC, Atlanta-USA, NAMRU-HIV-WRAIR, USA).

Bună stăpânire a instrumentelor Microsoft Office™ (Word™, Excel™ și PowerPoint™); Cunoștințe privind aplicațiile de grafică pe calculator (Adobe Illustrator™) și aplicațiile de statistică (Epi Info - CDC, Atlanta).

Competențele au fost dobândite în cadrul formării profesionale, seminariilor, în cadrul unor activități de voluntariat, în timpul liber, în cadrul formării altor studenți, colegi sau subordonați.

Categoria B

Titlul de „Profesor Bologna” acordat de „Alianța Națională a Organizațiilor Studentești din România” (decembrie 2007, reconfirmat în mai 2009);

Reprezentant național pe probleme de microbiologie (National Microbiology Focal Point) în relația cu Centrul European de Prevenire și Control al Bolilor (ECDC) (2007-2009);

Expert examinator al proiectelor de sănătate publică, pentru proiecte aplicate pentru finanțare la nivelul Comunității Europene (Luxembourg);

Membru în echipa de lucru sau coordonator al mai multor proiecte de cercetare și cercetare-dezvoltare la nivel național sau în colaborare internațională;

Consilier al ministrului sănătății (2001 și 2005-2007);

Punct focal pentru România, în relația cu EWRS (Rapid information exchange on Health Threats - EWRS) (2006-2007);

Șef al Unității de Management al Proiectelor cu Banca Mondială și Banca Europeană de Investiții (2005-2006);

Co-președinte a Comisiei Naționale de Epidemiologie (2005-2006);

Co-inițiator, moderator și coordonator al „Cercului de Microbiologie” (2000 -);

Membru al Comitetului Executiv OMS (Standing Committee of the EURO Regional Committee / SCRC) pentru Europa (2000-2001);

Membru fondator al grupului de lucru al rețelei de supraveghere epidemiologică pentru țările din Europa Centrală și de Est (2000);

Inițiator și realizator al fișei proiectului PHARE de asistență tehnică pentru îmbunătățirea sistemului de supraveghere și control al bolilor infecțioase în România (mai-noiembrie 2000), proiect care a fost aprobat în noiembrie 2000 și implementat în perioada 2003-2004 (circa **4 milioane EUR** fonduri nerambursabile) EuropeAid/113121/D/SV/RO;

Membru în colectivul de redacție sau în echipa de „peer-review” al unor publicații naționale și internaționale; Bacteriologia, Virusologia, Parazitologia și Epidemiologia (1993-2001), Romanian Archives of Microbiology and Immunology (2005-2009; 2015-2018), Infomedica, Maedica, Emerging Infectious Diseases, Eurosurveillance (2007-2009), Gastroenterology and Hepatology, African Journal of Microbiology Research, Clinical Reviews and Opinions, Infectio.ro, BMJ Case Reports, European Journal of Clinical Microbiology & Infectious Diseases, Plos One, Methods and Protocols, Antibiotics etc.

Lucrări: 587 comunicate (coordonator pentru unele dintre lucrările comunicate de către studenți) (26 cu rezumat publicat în reviste/volume cotate sau indexate Clarivate Analytics); 459 publicate (parte sunt articole de opinie), între acestea 40 sunt lucrări publicate în reviste sau volume indexate sau cotate Clarivate Analytics (anterior ISI Thomson) (autor, co-autor, colaborator); lucrări citate în peste 500 de reviste sau cărți naționale și internaționale; autor al unui curs de microbiologie (3 ediții); coautor la 4 cărți (volumul „Microbiologie Medicală” a apărut în 2 ediții); autor al volumului „Diagnosticul de laborator în microbiologie” (2 ediții); autor al primului raport tehnic „Supravegherea epidemiologică a infecției HIV / SIDA în România”, membru în echipa de redactare a două rapoarte ale Organizației Mondiale a Sănătății (publicate de editura OMS-EURO, Copenhaga); membru în echipa de redactare a trei rapoarte ale Centrului European de Control al Bolilor (ECDC); autor, coautor sau colaborator la redactarea a 23 capitole sau subcapitole în cărți și tratate medicale (naționale și internaționale); prim autor al unui manual pentru uzul studenților (1993).

Pentru evaluarea Indicelui Hirsch am utilizat datele privind citările pentru fiecare lucrare în parte, anexate, rezultând IH = 11.

Prof. dr. Mircea Ioan Popa



1. Sfetcu O, Cremenasiu D, Circiumaru S, Barhala M, Florescu R, Duca E, Cojan A, Marialaky E, Yanku MM, Irimia M, Dobrescu A, **Popa M**, Ion-Nedelcu N, Craciun D. Frequency of vaccine-related and therapeutic injections--Romania, 1998. MMWR Morb Mortal Wkly Rep. 1999;48(13):271-4 (12) FI: 12,888
 2. Sfetcu O, Cremenasiu D, Circiumaru S, Barhala M, Florescu R, Duca E, Cojan A, Marialaky E, Yanku MM, Irimia M, Dobrescu A, **Popa M**, Ion-Nedelcu N, Craciun D. Frequency of vaccine-related and therapeutic injections--Romania, 1998. JAMA. 1999;281(21):1981-2 FI: 47,661
 3. Hadgichristodoulou C, **Popa MI**, Afsar O, Vasileios D, Pirounaki M. Surveillance of communicable diseases in the Balkans. Lancet. 2000;355(9213):1465 (1) FI: 53,254
 4. Centers for Disease Control and Prevention (CDC). Outbreak of aseptic meningitis associated with multiple enterovirus serotypes--Romania, 1999. MMWR Morb Mortal Wkly Rep. 2000;49(29):669-71 (coordonator) (7) FI: 12,888
 5. Popescu Chisevescu D, Mihăilescu I, Popaza Mihăilescu G, Pasat L, Ion Nedelcu N, **Popa MI**. Injection practices among nurses – Vâlcea, România 1998. MMWR Morb Mortal Wkly Rep. 2001;50(4):59-61 (11) FI: 12,888
 6. Popescu Chisevescu D, Mihăilescu I, Popaza Mihăilescu G, Pasat L, Ion Nedelcu N, **Popa MI**. Injection practices among nurses - Valcea, Romania, 1998 (Reprinted from MMWR Morb Mortal Wkly Rep. 2001;50(4):59-61). JAMA. 2001;285(9):1149-50 FI: 47,661
 7. Ion-Nedelcu N, Craciun D, Pitigoi D, **Popa M**, Hennessey K, Roure C, Aston R, Zimmermann G, Pelly M, Gay N, Strebel P. Measles elimination: a mass immunization campaign in Romania. Am J Public Health. 2001;91(7):1042-5 (6) FI: 4,38
 8. Dentinger C, Pasat L, **Popa M**, Hutin YJF, Mast EE. Injection practices in Romania; Progress and challenges. Inf Control Hosp Epidemiol. 2004;25(1):30-35 (12) FI: 3,084
 9. Ibram S, Munteanu A, Stolica B, Enescu M, Savulescu C, Costinea R, **Popa MI**. An outbreak of gastroenteritis in a campsite in Romania, July 2007. Euro Surveill. 2007;12(8):E070816.1 (3) FI: 7,127
 10. Stavri H, Ene L, Duiculescu D, Murgoci Gh, Moldovan O, **Popa MI**, Popa L. Mycobacterial infections detection in HIV positive children using two serologic assays and tuberculin skin test. 2007. Lucrare prezentată poster la 13th International Congress of Immunology, Rio de Janeiro, Brazilia, 21-25 august 2007, lucrare publicată în volum indexat C A, ISBN 978-88-7587-379-0, CD ISBN 978-88-7587-380-6, 79-84
 11. Popovici F, Sarbu A, Nicolae O, Pistol A, Cucuiu R, Stolica B, Furtunescu F, Manuc M, **Popa MI**. West Nile fever in a patient in Romania, August 2008: case report. Euro Surveill. 2008;13(39).pii:18989 (9) FI: 7,127
 12. **Popa MI**, Popa GL. Listeriosis in Pregnancy: a Public Health Problem in Romania? Gineco.ro. 2009;5(1):58-61 FI: 0,053
 13. Popa GL, Vizitiu O, Georgescu R, Grigore L, Iarca C, Beldescu N, **Popa MI**. Antibiotic susceptibility of Group B Streptococcal strains in women of child-bearing age; Recommendations for prevention and control of perinatal Group B Streptococcal Disease. Gineco.ro. 2009;5(3):146-55 FI: 0,053
 14. Zaharia DC, Iancu C, Steriade A, Muntean A, Balint O, Popa VT, **Popa MI**, Bogdan MA. MicroDSC study of Staphylococcus epidermidis growth. BMC Microbiol. 2010;10:322 (7) FI: 2,829
 15. Stavri H, Ulea I, Radu DL, Gheorghiu Branaru M, Moldovan O, Bogdan MA, Tudose C, Raileanu M, Duiculescu D, Ene L, Olar V, Ionita C, Popa GL, **Popa MI**, Brennan PJ. Serodiagnosis of Environmental Mycobacterial Infections. J Microbiol Methods. 2011;86(3):283-290 (1) FI: 1,701
 16. Mereckiene J, Cotter S, Weber JT, Nicoll A, D'Ancona F, Lopalco PL, Johansen K, Wasley AM, Jorgensen P, Lévy-Bruhl D, Giambi C, Stefanoff P, Dematte L, O'Flanagan D; the VENICE project gatekeepers group. Influenza A(H1N1)pdm09 vaccination policies and coverage in Europe. Euro Surveill. 2012;17(4):pii=20064 (colaborator) (aprox. 60) FI: 7,127
- Available online:
<http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20064>
17. Stavri H, Bucurenci N, Ulea I, Costache A, Popa L, **Popa MI**. Use of recombinant purified protein derivative (PPD) antigens as specific skin test for tuberculosis. Indian J Med Res. 2012;136:799-807 (4) FI: 1,508
 18. Zaharia DC, Muntean A, Popa MG, Steriade A, Balint O, Micut R, Iftene C, Tofolean I, Popa VT, Baicus C, Bogdan MA, **Popa MI**. Comparative analysis of *Staphylococcus aureus* and *Escherichia coli* microcalorimetric growth. BMC Microbiol. 2013;13:171 (12) FI: 2,829
 19. Popa GL, Tanase I, Popa CA, Mastalier B, **Popa MI**, Cretu CM. Medical and surgical management of a rare and complicated case of multivisceral hydatidosis; 18 years of evolution. New Microbiol. 2014;37(3):387-391 (1) FI: 1,412
 20. Mihai MM, Holban AM, Giurcăneanu C, Popa LG, Buzea M, Filipov M, Lazăr V, Chifiriuc MC, **Popa MI**. Identification and phenotypic characterization of the most frequent bacterial etiologies in chronic skin ulcers. Rom J Morphol Embryol. 2014;55(4):1401-8 (25) FI: 0,912
 21. Mihai MM, Holban AM, Giurcăneanu C, Popa LG, Oanea RM, Lazar V, Chifiriuc MC, Popa M, **Popa MI**. Microbial biofilms: impact on the pathogenesis of periodontitis, cystic fibrosis, chronic wounds and medical device-related infections. Curr Top Med Chem. 2015;15(16):1552-76 (38) FI: 3,374
 22. Neguț AC, Chifiriuc MC, Săndulescu O, Streinu-Cercel A, Oprea M, Drăgulescu EC, Gheorghe I, Berciu I, Bleotu C, Popa M, Oțelea D, Tălăpan D, Dorobăț O, Codiță I, **Popa MI**, Streinu-Cercel A. Bacteriophage-driven inhibition of biofilm formation in Staphylococcus strains from patients attending a Romanian reference center for infectious diseases. FEMS Microbiol Lett. 2016 Aug 11. pii: fnw193. (2) FI: 1,735
 23. Cristea CV, Gheorghe I, Neacsu G, Galca R, Czobor I, Alexandru I, Chifiriuc MC, Lazar V, **Popa MI**. Staphylococcus sp Involvement in Community Acquired Urinary Tract Infections. Rom Biotech Letters. 2016;21(2):11413-417 (1) FI: 0,321
 24. Neguț AC, Streinu-Cercel A, Săndulescu O, Moțoi MM, Berciu I, **Popa MI**, Streinu-Cercel A. Bacteriophages – novel biotechnology tools available in clinical practice in Romania. Rom Biotech Letters. 2017;22(2):12492-495 FI: 0,321
 25. Dragomirescu CC, Lixandru BE, Coldea IL, Palade AM, Baltoiu M, Dinu S, Cristea CV, Manolescu L, **Popa MI**. Comparative analysis of different phenotypic and molecular methods used for the taxonomic identification of Corynebacterium spp. isolated from clinical samples in Romania. Rom Biotech Letters. 2017;22(5):12926-933 (SRI 0.16) (1) FI: 0,321
 26. Peneș N, Muntean AA, Moisoiu A, Muntean MM, Chirca A, Bogdan MA, **Popa MI**. An overview of resistance profiles ESKAPE pathogens from 2010-2015 in a tertiary respiratory center in Romania. Rom J Morphol Embryol. 2017;58(3):909-922 (4) (FI: 0,912)
 27. Muntean MM, Muntean AA, Gauthier L, Creton E, Cotellon G, **Popa MI**, Bonnin R, Naas T. Evaluation of the Rapid Carbapenem Inactivation Method (rCIM): a phenotypic screening test for carbapenemase producing Enterobacteriaceae. J Antimicrobial Chemotherapy. 2018;73(4):900-908 (11) (FI: 5,217)
 28. Mihai MM, Preda M, Lungu I, Gestal MC, **Popa MI**, Holban AM. Nanocoatings for Chronic Wound Repair - Modulation of Microbial Colonization and Biofilm Formation. Int J Mol Sciences. 2018;19(4):1179. (14) (FI: 3,687)
 29. Tamarozzi F, Akhan O, Cretu CM, Vutova K, Akinci D, Chipeva R, Ciftci T, Constantin CM, Massimo Fabiani, Golemanov B, Janta D, Mihăilescu P, Muhtarov M, Orsten S, Petruțescu M, Pezzotti P, Popa AC, Popa GL, **Popa MI**, Velev V, Siles-Lucas M, Brunetti B, Casulli C. Prevalence of abdominal cystic echinococcosis in rural Bulgaria, Romania, and Turkey: a cross-sectional, ultrasound-based, population study from the HERACLES project. Lancet Inf Dis. 2018;18(7):769-778 (21) (FI: 25,148)
 30. Georgescu SR, Mitran CI, Mitran MI, Caruntu C, Sarbu MI, Matei C, Nicolae I, Tocut SM, **Popa MI**, Tampa M. New Insights in the Pathogenesis of HPV Infection and the Associated Carcinogenic Processes: The Role of Chronic Inflammation and Oxidative Stress. J Immunol Res. 2018;2018:5315816. (all authors – equal) (16) (FI: 3,298)
 31. Tampa M, Mitran MI, Mitran CI, Sarbu MI, Matei C, Nicolae I, Caruntu A, Tocut SM, **Popa MI**, Caruntu C, Georgescu SR. Mediators of Inflammation—A Potential Source of Biomarkers in Oral Squamous Cell Carcinoma. J Immunol Res. 2018;2018:1061780. (5) (FI: 3,298)
 32. Georgescu SR, Tampa M, Mitran MI, Mitran CI, Sarbu MI, Nicolae I, Matei C, Caruntu C, Neagu M, **Popa MI**. Potential pathogenic mechanisms involved in the association between lichen planus and hepatitis C virus infection (Review). Exp Ther Med. 2019;17(2):1045-51 (2) (FI: 1,41)

33. Cristea D, Trandafir M, Bojinca VC, Ciontea AS, Andrei MM, Popa A, Lixandru BE, Militaru CM, Nascutiu AM, Predeteanu D, Ionescu R, Popescu C, Cotar AI, **Popa MI**, Spandidos DA, Codita I. Usefulness of complex bacteriological and serological analysis in patients with spondyloarthritis. *Exp Ther Med*. 2019;17(5):3465-76. (FI: 1,44)
34. Kissling E, Rose A, Emborg HD, et al., and European IVE group. Interim 2018/19 influenza vaccine effectiveness: six European studies, October 2018 to January 2019. *Eurosurveill*. 2019;24(8):pii=1900121. <https://doi.org/10.2807/1560-7917.ES.2019.24.1900121>. (FI: 7,127). (colaborator)
35. Cristea CV, Gheorghe I, Czobor Barbu I, Popa LI, Ispas B, Grigore GA, Bucatariu I, Popa GL, Angelescu MC, Velican A, Marutescu L, Popa M, Chifiriu MC, **Popa MI**. Snapshot of Phylogenetic Groups, Virulence, and Resistance Markers in *Escherichia coli* Uropathogenic Strains Isolated from Outpatients with Urinary Tract Infections in Bucharest, Romania. *BioMed Res Int*. 2019;5(1):1-8 5712371: doi.org/10.1155/2019/5712371 (3) (FI: 2,583).
36. Manolescu LSC, Boeru C, Căruntu C, Goldis M, Jugulete G, Marin M, Popa GL, Preda M, Radu MC, **Popa MI**. A Romanian experience of syphilis in pregnancy and childbirth. *Midwifery*. 2019;78:58-63 (FI: 2,048)
37. Mitran MI, Nicolae I, Tampa M, Mitran CI, Caruntu C, Sarbu MI, Ene CD, Matei C, Georgescu SR, **Popa MI**. Reactive Carbonyl Species as Potential Pro-Oxidant Factors Involved in Lichen Planus Pathogenesis. *Metabolites*. 2019;9(10):213. (FI: 3,303).
38. Mitran CI, Nicolae I, Mitran MI, Tampa M, Caruntu C, Sarbu MI, Ene CD, Matei C, Ionescu AC, Georgescu SR, **Popa MI**. The Relationship between the Soluble Receptor for Advanced Glycation End Products and Oxidative Stress in Patients with Palmoplantar Warts. *Medicina*. 2019;55(10):706. (1) (FI: 1,467).
39. Trifu AI, **Popa MI**, Drăgoi AM. The comorbidity of schizophrenia and alcohol: from cognitive destruction to social isolation. *Lucrare prezentată la 10th ICEEPSY 2019 (International Conference on Education and Educational Psychology)*, Barcelona, Spania, 9-12 Octombrie 2019. *Lucrarea este publicată în The European Proceedings of Social & Behavioural Sciences*; <https://doi.org/10.15405/epsbs.2019.11.87>; ISSN: 2357-1330, de Future Academy (www.FutureAcademy.org). 2019:787-794 (publicația este indexată Clarivate Analytics)
40. Dragomirescu CC, Lixandru BE, Coldea IL, Corneli ON, Pana M, Palade AM, Cristea VC, Suciu I, Suciu G, Manolescu LSC, Popa LG, Popa. Antimicrobial Susceptibility Testing for *Corynebacterium* Species Isolated from Clinical Samples in Romania *Antibiotics (Basel)*. 2020;9(1). pii: E31. doi: 10.3390/antibiotics9010031. (FI: 2,921)

Numărul de citări al fiecărui articol ISI

1. Sfetcu O, Cremenasiu D, Circiumaru S, Barhala M, Florescu R, Duca E, Cojan A, Marialaky E, Yanku MM, Irimia M, Dobrescu A, **Popa M**, Ion-Nedelcu N, Craciun D. Frequency of vaccine-related and therapeutic injections--Romania, 1998. *MMWR Morb Mortal Wkly Rep*. 1999;48(13):271-4 (Current impact factor: 12,888)
- 16 citări, citat de: (12) (2 autocitări)
1. Wasley A, Alter MJ. Epidemiology of hepatitis C: Geographic differences and temporal trends. *Semin Liver Dis*. 2000;20(1):1-16 (Current impact factor: 5,5)
 2. Alter MJ, Hutin YJF, Armstrong GL. 9 Epidemiology of hepatitis C. *Biomedical Research Reports*. 2000;2(C):169-83 (carte, editura ELSEVIER, are RG IF 1,22)
 3. Chisevescu P, Mihailescu I, Mihailescu GP, et al. Injection practices among nurses - Vâlcea, Romania, 1998. *MMWR Morb Mortal Wkly Rep*. 2001;50(4):59-61 (Current impact factor: 11,483)
 4. Flaitz C, Wullbrandt B, Sexton J, et al. Prevalence of orodental findings in HIV-infected Romanian children. *Pediatr Dent*. 2001;23(1):44-50 (Current impact factor: 1,947)
 5. Marx G, Martin SR, Chicoine JF, Alvarez F. Long-term follow-up of chronic hepatitis B virus infection in children of different ethnic origins. *J Infect Dis*. 2002;186(3):295-301 (Current impact factor: 6,273)
 6. Hutin YJF, Hauri AM, Armstrong GL. Use of injections in healthcare settings worldwide, 2000: Literature review and regional estimates. *BMJ*. 2003;327(7423):1075-78 (Current impact factor: 17,215)
 7. Dentinger C, Pasat L, Popa M, et al. Injection Practices in Romania: Progress and Challenges. *Infect Control Hosp Epidemiol*. 2004;25(1):30-35 (Current impact factor: 4,175)
 8. Hauri AM, Armstrong GL, Hutin YJF. The global burden of disease attributable to contaminated injections given in health care settings. *Int J STD AIDS*. 2004;15(1):7-16 (Current impact factor: 1,35)
 9. Cocu M, Thorne C, Mătușă R, et al. Mother-to-child transmission of HIV infection in Romania: Results from an education and prevention programme. *AIDS Care*. 2005;17(1):76-84 (Current impact factor: 1,824)
 10. Hutin YJF. Acting upon evidence: Progress towards the elimination of unsafe injection practices in India. *Indian Pediatr*. 2005;42(2):111-15 (Current impact factor: 1,152)
 11. Janjua NZ, Akhtar S, Hutin YJF. Injection use in two districts of Pakistan: Implications for disease prevention. *Int J Qual Health Care*. 2005;17(5):401-8 (Current impact factor: 2,342)
 12. Ruta SM, Matusa RF, Sultana C, et al. High prevalence of hepatitis B virus markers in Romanian adolescents with human immunodeficiency virus infection. *MedGenMed*. 2005;7(1):68 (Nu are factor de impact)
 13. Ruta SM, Matusa RF, Sultana C, et al. High prevalence of hepatitis B virus markers in Romanian adolescents with human immunodeficiency virus infection. *J Int AIDS Soc*. 2005;7:68. (Current impact factor: 5,135)
 14. Zacharakis G, Koskinas J, Kotsiou S, et al. Natural history of chronic hepatitis B virus infection in children of different ethnic origins: A cohort study with up to 12 years' follow-up in Northern Greece. *J Pediatr Gastroenterol Nutr*. 2007;44(1):84-91 (Current impact factor: 2,799)
 15. Manzat Saplacan RM, Mircea PA, Valean SD, et al. The long-term evolution of chronic hepatitis B acquired in childhood. *J Gastrointest Liver Dis*. 2009;18(4):433-38 (Current impact factor: 1,837)
 16. Bhunia R, Hutin Y, Ramkrishnan R, et al. Reducing use of injections through interactional group discussions: A randomized controlled trial. *Indian Pediatr*. 2010;47(5):409-14 (Current impact factor: 1,152)
2. Sfetcu O, Cremenasiu D, Circiumaru S, Barhala M, Florescu R, Duca E, Cojan A, Marialaky E, Yanku MM, Irimia M, Dobrescu A, Popa M, Ion-Nedelcu N, Craciun D. Frequency of vaccine-related and therapeutic injections--Romania, 1998. *JAMA*. 1999;281(21):1981-2 (Current impact factor: 47,661)
- Având în vedere subiectul articolului care apare la nr. 1, revista americană JAMA (factor de impact 44,405) a decis „reprint”-area articolului. Citările apar la articolul 1.
3. Hadgichristodoulou C, **Popa MI**, Afsar O, Vasileios D, Pirounaki M. Surveillance of communicable diseases in the Balkans. *Lancet*. 2000;355(9213):1465 (Current impact factor: 53,254)
- 3 citări (1), citat de:
1. Curate F. A brucelose em paleopatologia: um estudo de caso proveniente da necrópole Cristã de Cacula Velha. *Antropol Port*. 2003/2004;20/21:209-35 (Este indexată BDI.)
 2. Curate F. Two possible cases of brucellosis from a Clarist monastery in Alcácer do Sal, southern Portugal. *Int J Osteoarchaeol*. 2006;16(5):453-58 (Current impact factor: 1,038)

3. Turfa JM. Divining the etruscan world: The brontoscopic calendar and religious practice. 2012;1-416 (Nu are factor de impact. Este o carte).

4. Centers for Disease Control and Prevention (CDC). Outbreak of aseptic meningitis associated with multiple enterovirus serotypes--Romania, 1999. MMWR Morb Mortal Wkly Rep. 2000;49(29):669-71 (coordonator al investigației) (Current impact factor: **12.888**)

9 citări, citat de: (7)

1. Harwood VJ. Detection and Occurrence of Indicator Organisms and Pathogens

Water Environment Research, Vol. 73, No. 5, Literature Reviews [CD-ROM content] (2001), pp. 1-33 (Nu are factor de impact. Este o carte).

2. Lai PC, Huang YT, Wang PJ. A Seasonal Outbreak of Pediatric Aseptic Meningitis in Eastern Taiwan: Clinical Presentations and Laboratory Analyses. Tzu Chi Med J. 2006; 18:423-426 (Nu are factor de impact, dar **este indexată C A**)

3. Machado BC, Ferreira RD, Carmona RD, Timenetsky MD. Aseptic meningitis by echovirus 30 in São Paulo state, Brazil. Braz J Microbiol. 2007;38(1):97-103 (Current impact factor: **1,81**).

4. Sinclair RG, Jones EL, Gerba CP. Viruses in recreational water-borne disease outbreaks: A review. J Appl Microbiol. 2009;107(6):1769-80. (Current impact factor: **2,16**)

5. Park SK, Park B, Ki M, et al. Transmission of Seasonal Outbreak of Childhood Enteroviral Aseptic Meningitis and Hand-foot-mouth Disease. J Korean Med Sci. 2010;25(5):677-683 (Current impact factor: **1,459**)

6. Cosic G, Durić P, Milosevic V, et al. Ongoing outbreak of aseptic meningitis associated with echovirus type 30 in the City of Novi Sad, Autonomous Province of Vojvodina, Serbia, June – July 2010. Euro Surveill. 2010;15(32):pii=19638

(Current impact factor: **7,202**)

7. Mohseni MM, Wilde JA. Viral meningitis: which patients can be discharged from the emergency department? Am J Emerg Med. 2012;43(6):1181-87 (Current impact factor: **1,494**)

8. Wolfaardt M, Buchner A, Myburgh M. Molecular characterisation of enteroviruses and clinical findings from a cluster of paediatric viral meningitis cases in Tshwane, South Africa 2010–2011. J Clin Virol. 2014;61(3):400-5 (Current impact factor: **3,051**)

9. Băicuș A, Persu A, Popa GL, Popa MI. Echovirus Serotypes Isolated In An Aseptic Meningitis Outbreak In Romania (2007). Romanian Archives. 2017;76(1):56-60.

5. Popescu Chisevescu D, Mihăilescu I, Popaza Mihăilescu G, Pasat L, Ion Nedelcu N, **Popa MI**. Injection practices among nurses – Vâlcea, România 1998. MMWR Morb Mortal Wkly Rep. 2001;50(4):59-61. (Current impact factor: **12.888**)

18 citări, citat de: (11)

1. Remez L. Whether Americans seek HIV testing is linked to race and perceived risk. Perspectives on Sexual and Reproductive Health. 2002;34(2):106 (Current impact factor: **5,045**).

2. Hamers FF, Downs AM. HIV in central and eastern Europe. Lancet. 2003;361(9362):1035-44 (Current impact factor: **47,831**)

3. Dziekan G, Chisholm D, Johns B, et al. The cost-effectiveness of policies for the safe and appropriate use of injection in healthcare settings. Bull World Health Org. 2003;81(4):277-85 (Current impact factor: **4,939**)

4. Hutin YJF, Hauri AM, Armstrong GL. Use of injections in healthcare settings worldwide, 2000: Literature review and regional estimates. BMJ. 2003;327(7423):1075-78 (Current impact factor: **17,215**)

5. Schlagenhauf P, Tschopp A, Johnson R, et al. Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study. BMJ. 2003;327(7423):1078

(Current impact factor: **17,215**)

6. Hauri AM, Armstrong GL, Hutin YJF. The global burden of disease attributable to contaminated injections given in health care settings. Int J STD AIDS. 2004;15(1):7-16 (Current impact factor: **1,35**)

7. Ruta SM, Matusa RF, Sultana C, et al. High prevalence of hepatitis B virus markers in Romanian adolescents with human immunodeficiency virus infection. MedGenMed. 2005;7(1):68 (Nu are factor de impact.)

8. Musa OI. Injection safety practice among healthworkers in static immunization centres in a Nigerian urban community. Trop Doc. 2006;36(3):185-86 (Current impact factor: **0,45**)

9. Johnson BT, Buzducea D. HIV-positive Romanian adolescents: acquisition routes, risk behaviors, and psychological correlates. AIDS Behav. 2007;11(5):716-25

(Current impact factor: **2,916**)

10. Giubelan L, Cupșa A, Diaconescu I, Dumitrescu F. Factorii de risc ai infecției cu virusul hepatitic B la adultul tânăr. Ro J Infect Dis. 2007;10(1):46-50 (Nu are factor de impact. Este indexată BDI.)

11. Ismail NA, Aboul Ftouh AM, El-Shoubary WH, Mahaba H. Safe injection practice among health-care workers in Gharbiya Governorate, Egypt. East Mediterr Health J. 2007;13(4):893-906 (Current impact factor: **0,628**)

12. Gayle HD. HIV Prevention. Global HIV/AIDS Medicine. 2008;91-100

(Nu are factor de impact. Este capitol de carte.)

13. Xu Yaru. Microbiological monitoring of air in hospital wards and hospital infection. North China Coal Medical College. 2008;10(4):464-66 (Nu are factor de impact.)

14. Wiedenmayer KA, Weiss S, Chattopadhyay C, et al. Simplifying paediatric immunization with a fully liquid DTP-HepB-Hib combination vaccine: evidence from a comparative time-motion study in India. Vaccine. 2009;27(5):655-9. (Current impact factor: **3,269**).

15. Lazăr F. Achieving Universal Access for People Affected by HIV/AIDS and Vulnerable Groups from Romania: Supporting Community Sector Involvement and Advocacy. A Supplement of Social Work Review. 2011;312 (Nu are factor de impact. Este volum)

16. Henderson DK. Human immunodeficiency virus in health care settings. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. 2014;3361-75

(Nu are factor de impact. Este capitol de carte.)

17. Ganesh SA, Raghunath N, Balaji S K. Assessment of safe injection practices and disposal methods among nursing personnel at health care centres of Hoskote-Rural Bengaluru, India. J Indian Assoc Public Health Dent. 2015;13(4):475-8. (Nu are factor de impact. Este indexată BDI.)

18. Anwar MM, Lotfy AA, Alrashidy AA. Safe injection awareness and practices among nursing staff in an Egyptian and a Saudi hospital. J Egyptian Public Health Assoc. 2019;94(1):21. (**C A fara IF**).

6. Popescu Chisevescu D, Mihăilescu I, Popaza Mihăilescu G, Pasat L, Ion Nedelcu N, **Popa MI**. Injection practices among nurses - Valcea, Romania, 1998 (Reprinted from MMWR Morb Mortal Wkly Rep. 2001;50(4):59-61). JAMA. 2001;285(9):1149-50

(Current impact factor: **47.661**)

Având în vedere subiectul articolului care apare la nr. 5, revista americană JAMA (factor de impact 44,405) a decis „reprint”-area articolului. Citările apar la articolul 5.

7. Ion-Nedelcu N, Craciun D, Pitigoi D, **Popa M**, Hennessey K, Roure C, Aston R, Zimmermann G, Pelly M, Gay N, Strebel P. Measles elimination: a mass immunization campaign in Romania. Am J Public Health. 2001;91(7):1042-5

(Current impact factor: **4.38**)

12 citări, citat de: (6)

1. Pistol A, Hennessey K, Pitigoi D, et al. Progress toward measles elimination in Romania after a mass vaccination campaign and implementation of enhanced measles surveillance. J Infect Dis. 2003;187(Suppl 1):S217-22 (Current impact factor: **6,273**)

2. Spika JS, Wassilak S, Pebody R, et al. Measles and rubella in the World Health Organization European region: diversity creates challenges. J Infect Dis. 2003;187(Suppl 1):S191-7 (Current impact factor: **6,273**)

3. Pless RP, Bentsi-Enchill AD, Duclos P. Monitoring vaccine safety during measles mass immunization campaigns: clinical and programmatic issues. *J Infect Dis*. 2003;187(Suppl 1):S291-8 (Current impact factor: 6,273)
4. World Health Organization. Field guide for planning and implementing supplemental immunization activities for measles and rubella. 2004. (Nu are factor de impact. Este volum.)
5. Mayxay M, Khomthilat T, Souvannasing P, et al. Factors associated with a measles outbreak in children admitted at Mahosot Hospital, Vientiane, Laos. *BMC Public Health*. 2007;7:193 (Current impact factor: 2,265)
6. Akande TM. A review of measles vaccine failure in developing countries. *Niger Med Pract*. 2007;52(5-6):112-16 (Nu are factor de impact.)
7. Stratton K, Ford A, Rusch E, Clayton EW. Injection-Related Adverse Events. 2011 (Nu are factor de impact. Este carte.)
8. Stratton K, Ford A, Rusch E, Clayton EW. Measles, Mumps, and Rubella Vaccine. 2011 (Nu are factor de impact. Este volum.)
9. 马超, et al. 世界卫生组织各区域和部分国家的消除麻疹免疫策略. *中国疫苗和免疫*. 2014;20(3):254-63 (Nu are factor de impact.)
10. Strebel PM, Papania MJ, Halsey NA. Capítulo 19: Vacuna anti-sarampión. (Nu are factor de impact. Este volum.)
11. Plans-Rubió P. Low percentages of measles vaccination coverage with two doses of vaccine and low herd immunity levels explain measles incidence and persistence of measles in the European Union in 2017-2018. *Eur J Clin Microbiol Infect Dis*. 2019. doi: 10.1007/s10096-019-03604-0 (Current impact factor: 2,591).
12. Schönfeld, S., Niewald, A., Matysiak-Klose, D. et al. Masernimpfkampagnen – internationale Erfahrungen. *Präv Gesundheitsf*. 2020: doi.org/10.1007/s11553-019-00757-w (indexata C A).

8. Dentinger C, Pasat L, **Popa M**, Hutin YJF, Mast EE. Injection practices in Romania; Progress and challenges. *Inf Control Hosp Epidemiol*. 2004;25(1):30-35

(Current impact factor: 3.084)

14 citări, citat de: (12)

1. Janjua NZ, Akhtar S, Hutin, YJF. Injection use in two districts of Pakistan: Implications for disease prevention. *Int J Qual Health Care*. 2005;17(5):401-8 (Current impact factor: 2,342)
2. Ruta S, Cernescu C. Influence of social changes on the evolution of HIV infection in Romania. *Int J Environ Stud*. 2008;65(4):501-13 (indexată C A)
3. Chunxiang F, Bike Z, Lijie Z, et al. Injection safety assessments in two Chinese provinces, 2001-2009: Progress and remaining challenges. *International Health*. 2012;4(4):295-302 (Current impact factor: 1,784)
4. Zehender G, Ebranati E, Gabanelli E, et al. Spatial and temporal dynamics of hepatitis B virus D genotype in Europe and the Mediterranean basin. *PLoS One*. 2012;7(5):e37198 (Current impact factor: 2,806)
5. Hadaway L. Needlestick injuries, short peripheral catheters, and health care worker risks. *J Infusion Nursing*. 2012;35(3):164-78 (indexată C A)
6. Ider BE, Adams J, Morton A, et al. Infection control systems in transition: The challenges for post-Soviet Bloc countries. *J Hosp Infect*. 2012;80(4):277-87 (Current impact factor: 3,126)
7. Ford, K. Survey of syringe and needle safety among student registered nurse anesthetists: Are we making any progress? *AANA J*. 2013;81(1):37-42 (SJR: 0,653)
8. Gadzama GB, Bawa SB, Ajinoma Z, et al. Injection safety practices in a main referral hospital in northeastern Nigeria. *Niger J Clin Pract*. 2014;17(2):134-39 (Current impact factor: 0,615)
9. Markovic-Denic L, Maksimovic N, Marusic V, et al. Occupational exposure to blood and body fluids among health-care workers in Serbia. *Med Princ Pract*. 2014;24(1):36-41 (Current impact factor: 1,469)
10. Zehender G, Ebranati E, Gabanelli E, et al. Enigmatic origin of hepatitis B virus: An ancient travelling companion or a recent encounter? *World J Gastroenterol*. 2014;20(24):7622-34 (Current impact factor: 3,365)
11. Ann Marie Kimball AM. Risky Trade: Infectious Disease in the Era of Global Trade. Ed. Routledge (Taylor and Francis Group). 2016 (carte)
12. Matsubara C, Sakisaka K, Sychareun V, Phensavanh A, Ali M. Prevalence and risk factors of needle stick and sharp injury among tertiary hospital workers, Vientiane, Lao PDR. *J Occupational Health*. 2017;17-0084. (Current impact factor: 1,848)
13. Ghahfarokhi MM, Masoudiyekta L, Khajeali N. The level of safety standards in implementing therapeutic and caring procedures by emergency department personnel. *Nurs Open*. 2018;6(1):109-115 (indexata CA).
14. Hayashi T, Hutin YJ, Bulterys M, et al. Injection practices in 2011–2015: a review using data from the demographic and health surveys (DHS). *BMC Health Serv Res*. 2019;19(1):600. (Current impact factor: 1,932)

9. Ibram S, Munteanu A, Stolica B, Enescu M, Savulescu C, Costinea R, **Popa MI**. An outbreak of gastroenteritis in a campsite in Romania, July 2007. *Euro Surveill*. 2007;12(8):E070816.1 (Current impact factor: 7.127)

6 citări (3), citat de:

1. Doyle ME. Survival and Growth of *Clostridium perfringens* during the Cooling Step of Thermal Processing of Meat Products. *FRI Briefings*. 2002 (În volum)
2. Doyle ME, Kaspar C, Archer J, Klos R. White paper on human illness caused by *Salmonella* from all food and non-food vectors. *FRI Briefings*. 2009 (În volum)
3. Sharifi Yazdi MK, Akbari A, Soltan Dallal MM. Multiplex polymerase chain reaction (PCR) assay for simultaneous detection of shiga-like toxin (stx1 and stx2), intimin (eae) and invasive plasmid antigen H (ipaH) genes in diarrheagenic *Escherichia coli*. *Afr J Biotechnol*. 2011;10(9):1522-1526 (indexată BDI)
4. de Oliveira MMM, Brugnera DF, do Nascimento JA, et al. Cinnamon essential oil and cinnamaldehyde in the control of bacterial biofilms formed on stainless steel surfaces. *Eur Food Res Technol*. 2012;234(5):821-32 (Current impact factor: 1,664)
5. de Oliveira MMM, Brugnera DF, do Nascimento JA, Piccoli RH. Control of planktonic and sessile bacterial cells by essential oils. *Food Bioprocess*. 2012;90(4):809-18 (Current impact factor: 1,97)
6. Kambhampati AK, Marsh ZA, Hlavsa MC, et al. Prevention and Control of Youth Camp–Associated Acute Gastroenteritis Outbreaks. *J Pediatric Infect Dis Soc*. 2018;8(5):322-399. doi: 10.1093/jpids/piy068. (Current impact factor: 2,456)

10. Stavri H, Ene L, Duiculescu D, Murgoci G, Moldovan O, **Popa MI**, Popa L. Mycobacterial infections detection in HIV positive children using two serologic assays and tuberculin skin test. 2007. Lucrare prezentată la 13th International Congress of Immunology, Rio de Janeiro, Brazilia, 21-25 august 2007 și publicată în volum cotate ISI, ISBN 978-88-7587-379-0, CD ISBN 978-88-7587-380-6, 79-84

2 citări, citat de:

1. Stavri H, Ene L, Popa GL, et al. Comparison of Tuberculin Skin Test with a Whole-Blood Interferon Gamma Assay and ELISA, in HIV positive children and adolescents with TB. *Rom Archives Microbiol Immunol*. 2009;68(1):14-19 (Este indexată BDI.)
2. Ene L, Stavri H, Nicolaescu O, et al. The clinical significance of the tests for diagnosis of tuberculous infection for the diagnosis of tuberculosis in HIV-infected children and adolescents. *Ro J Infect Dis*. 2009;12(1):20-31 (Este indexată BDI.)

11. Popovici F, Sarbu A, Nicolae O, Pistol A, Cucuiu R, Stolica B, Furtunescu F, Manuc M, **Popa MI**. West Nile fever in a patient in Romania, August 2008: case report. *Euro Surveill*. 2008;13(39).pii:18989 (Current impact factor: 7.127)

13 citări, citat de: (9)

1. Pradel JA, Martin T, Rey D, et al. Is *Culex modestus* (Diptera: Culicidae), vector of West Nile virus, spreading in the dombes area, France? *J Med Entomol*. 2009;46(6):1269-81 (Current impact factor: 1,65)

2. Brault AC. Changing patterns of west nile virus transmission: Altered vector competence and host susceptibility. *Vet Res.* 2009;40(2):43 (Current impact factor: 2,798)
3. Rossi SL, Ross TM, Evans JD. West nile virus. *Clin Lab Med.* 2010;30(1):47-65 (Current impact factor: 2,396)
4. Eiden M, Vina-Rodriguez A, Hoffmann B, et al. Two new real-time quantitative reverse transcription polymerase chain reaction assays with unique target sites for the specific and sensitive detection of lineages 1 and 2 West Nile virus strains. *J Vet Diagn Invest.* 2010;22(5):748-53 (Current impact factor: 0,925)
5. Reusken C, De Vries A, Den Hartog W, et al. A study of the circulation of West Nile virus in mosquitoes in a potential high-risk area for arbovirus circulation in the Netherlands, "De Oostvaardersplassen". *J Eur Mosq Control Assoc.* 2010;28:69-83. (Nu are factor de impact.)
6. ECDC Threat Assessment. Cluster of human cases of West Nile virus infection in Greece, August 2010. <http://www.infekce.cz/Zpravy/MZDR-WNF2.pdf>
7. Bezirtzoglou C, Dekas K, Charvalos E. Climate changes, environment and infection: Facts, scenarios and growing awareness from the public health community within Europe. *Anaerobe.* 2011;17(6):337-40 (Current impact factor: 2, 278)
8. Reusken CBEM, Van Maanen C, Martina BE, et al. West Nile virus is expanding in Europe. *Ned Tijdschr Geneesk.* 2011;155(39):1747-50 (indexată C A)
9. Van Maanen K, Reusken C, Martina B, et al. West Nile virus in advance: Alertness is needed. *Tijdschr Diergeneesk.* 2011;136(7):518-20 (Current impact factor: 0,01)
10. Mantke OD. Arboviral Encephalitis—Epidemiology, Diagnostics and Surveillance in the Face of Changing Environments. 2011 (Habilitation thesis)
11. Di Sabatino D, Bruno R, Sauro F, et al. Epidemiology of West Nile Disease in Europe and in the Mediterranean Basin from 2009 to 2013. *BioMed Res Int.* 2014;2014:907852 (Current impact factor: 2,476)
12. Rezza G. West Nile virus infections in South-eastern Europe and in the Eastern Mediterranean area. *JMID.* 2014;1:S10-16 (Este indexată BDI.)
13. Conte A, Candeloro L, Ippoliti C, et al. Spatio-Temporal Identification of Areas Suitable for West Nile Disease in the Mediterranean Basin and Central Europe. *PLoS One.* 2015;10(12):e0146024 (Current impact factor: 2,806)
12. Popa MI, Popa GL. Listeriosis in Pregnancy: a Public Health Problem in Romania? *Gineco.ro.* 2009;5(1):58-61 (a avut factor de impact 0,053)
13. Popa GL, Vizitiu O, Georgescu R, Grigore L, Iarca C, Beldescu N, Popa MI. Antibiotic susceptibility of Group B Streptococcal strains in women of child-bearing age; Recommendations for prevention and control of perinatal Group B Streptococcal Disease. *Gineco.ro.* 2009;5(3):146-55 (a avut factor de impact 0,053)
14. Zaharia DC, Iancu C, Steriade A, Muntean A, Balint O, Popa VT, Popa MI, Bogdan MA. MicroDSC study of Staphylococcus epidermidis growth. *BMC Microbiol.* 2010;10:322 (Current impact factor: 2.829)
- 11 citări, citat de: (7) (1 autocitare)
1. Paredes Puente J. Desarrollo de un sistema para el análisis impedimétrico de biocapas bacterianas incluyendo biosensores, protocolos y plataforma experimental y su aplicación en implantes de acceso venoso central. (2012) (teză de doctorat)
2. Zaharia DC, Popa MG, Steriade AT, et al. Microcalorimetry a new method for bacterial characterisation. *Pneumologia.* 2013;62(4):232-235 (Este indexată BDI)
3. Zaharia DC, Muntean AA, Popa MG, et al. Comparative analysis of Staphylococcus aureus and Escherichia coli microcalorimetric growth. *BMC Microbiol.* 2013;13(1):171 (Current impact factor: 2,644)
4. Vazquez C, Lago N, Mato MM, et al. Microcalorimetric study of the growth of Enterococcus faecalis, Pseudomonas aeruginosa and their mixtures in an enriched culture medium. *J Thermal Anal Calorim.* 2015;121(1):463-68 (Current impact factor: 1,953)
5. Staicu T, Cîrcu V, Ioniță G, et al. Analysis of bimodal thermally-induced denaturation of type I collagen extracted from calfskin. *RSC Advances.* 2015;5(48):38391-406 (Current impact factor: 3,108)
6. Braissant O, Bachmann A, Bonkat G. Microcalorimetric assays for measuring cell growth and metabolic activity: methodology and applications. *Methods.* 2015;76:27-34 (Current impact factor: 3,802)
7. Vazquez C, Lago N, Mato MM, et al. Study of the growth of Enterococcus faecalis, Escherichia coli and their mixtures by microcalorimetry. *J Thermal Anal Calorim.* 2016;1-6 (Current impact factor: 1,953)
8. García AH, Herrmann AM, Hakansson S. Isothermal microcalorimetry for rapid viability assessment of freeze-dried Lactobacillus reuteri. *Process Biochemistry.* 2017;55:49-54 (Current impact factor: 2,497)
9. Sokhadze VM, Namchevadze EN, Kiziria EN, et al. The study of time-course toxic impact of Ni on the thermostability of the soil Arthrobacter oxydans bacterial cell culture. *Annals Agrar Sci.* 2017;15(2):169-176 (Este indexată BDI)
10. Popa M, Ene R, Streinu-Cercel A, et al. Algic Syndrome in Osteoarticular Infectious Pathology; Detection and Rapid Treatment of the Causative Agent Using Microcalorimetry. *Proceedings of The 14th National Congress of Urogynecology (7-9 September 2017) and of The National Conference of The Romanian Association for the study of pain (26-27 October 2017), Bucharest.* Filodiritto Publisher. 2017:589-594 (Indexat Clarivate Analytics)
11. Aveledo R, Aveledo A, Vázquez C, et al. Study of bacterial sensitivity in zinc sulfate solutions by microcalorimetry. *J Therm Anal Calorim.* 2018;33:773-777. (Current impact factor: 1,953)
15. Stavri H, Ulea I, Radu DL, Gheorghiu Branaru M, Moldovan O, Bogdan MA, Tudose C, Raileanu M, Duiculescu D, Ene L, Olar V, Ionita C, Popa GL, Popa MI, Brennan PJ. Serodiagnosis of Environmental Mycobacterial Infections. *J Microbiol Methods.* 2011;86(3):283-290 (Current impact factor: 1.701)
- 3 citări, citat de: (1)
1. Ulea I, Stavri H. Thin layer chromatography characterization of ELISA specific glycolipids antigens immunomagnetically purified from environmental mycobacteria. *Rom Arch Microbiol Immunol.* 2013;72(2):105-20 (Este indexată BDI)
2. Moisoiu A, Grigoriu LA, Popa MI. Infections caused by non-tuberculous mycobacteria. *Infectio.ro.* 2014;39(3):24-28 (Este indexată BDI)
3. Haworth CS, Banks J, Capstick T, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). *Thorax.* 2017;72(Suppl 2):ii1-64. (Current impact factor: 8,272).
16. Mereckiene J, Cotter S, Weber JT, Nicoll A, D'Ancona F, Lopalco PL, Johansen K, Wasley AM, Jorgensen P, Lévy-Bruhl D, Giambi C, Stefanoff P, Dematte L, O'Flanagan D; the VENICE project gatekeepers group. Influenza A(H1N1)pdm09 vaccination policies and coverage in Europe. *Euro Surveill.* 2012;17(4):pii=20064 (colaborator) (Current impact factor: 7,127) DOI: 10.2807/ese.17.04.20064-en citat de: (peste 50)
1. Partinen M, Saarenpää-Heikkilä O, Ilveskoski I, et al. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. *PLoS One.* 2012;7(3):e33723 (Current impact factor: 2,806)
2. Wijnans L, Lecomte C, de Vries C, et al. The incidence of narcolepsy in Europe: before, during, and after the influenza A (H1N1) pdm09 pandemic and vaccination campaigns. *Vaccine.* 2013;31(8):1246-54 (Current impact factor: 3,624)
3. Persson I, Granath F, Askling J, et al. Risks of neurological and immune-related diseases, including narcolepsy, after vaccination with Pandemrix: a population- and registry-based cohort study with over 2 years of follow-up. *J Intern Med.* 2014;275(2):172-90 (Current impact factor: 7,598)
4. Pebody, R. G., Green, H. K., Andrews, N., et al. Uptake and impact of a new live attenuated influenza vaccine programme in England: early results of a pilot in primary school-age children, 2013/14 influenza season. *Euro Surveill.* 2014;19(22):20823 (Current impact factor: 5,722)
5. Mereckiene J, Cotter S, Nicoll A, et al. Seasonal influenza immunisation in Europe. Overview of recommendations and vaccination coverage for three seasons: pre-pandemic (2008/09), pandemic (2009/10) and post-pandemic (2010/11). *Euro Surveill.* 2014;19(16):20780 (impact factor: 7,202)

6. Sammon CJ, Snowball J, McGrogan A, & De Vries CS. Evaluating the hazard of foetal death following H1N1 influenza vaccination; a population based cohort study in the UK GPRD. *PLoS One*. 2012;7(12):e51734 (Current impact factor: 3,234)
7. Principi N, Marchisio P, Terranova L, et al. Impact of vitamin D administration on immunogenicity of trivalent inactivated influenza vaccine in previously unvaccinated children. *Hum Vaccin Immunother*. 2013;9(5):969-74 (Current impact factor: 2,157)
8. Trotta F, Da Cas R, Alegiani SS, et al. Evaluation of safety of A/H1N1 pandemic vaccination during pregnancy: cohort study. *BMJ*. 2014;348:g3361 (Current impact factor: 2,271)
9. Nicoll A, Brown C, Karcher F, et al. Developing pandemic preparedness in Europe in the 21st century: experience, evolution and next steps. *Bul World Health Organ*. 2012;90(4):311-17 (Current impact factor: 4,939)
10. Chowell G, Nishiura H, Viboud C. Modeling rapidly disseminating infectious disease during mass gatherings. *BMC Med*. 2012;10(1):159 (Current impact factor: 7,36)
11. Flicoteaux R, Pulcini C, Carrieri P, et al. Correlates of general practitioners' recommendations to patients regarding vaccination for the 2009–2010 pandemic influenza (A/H1N1) in France: implications for future vaccination campaigns. *Vaccine*. 2014;32(20):2281-87 (Current impact factor: 3,235)
12. Cleary BJ, Rice Ú, Eogan M, et al. 2009 A/H1N1 influenza vaccination in pregnancy: uptake and pregnancy outcomes - a historical cohort study. *Eur J Obstet Gynecol Reprod Biol*. 2014;178:163-68 (Current impact factor: 1,695)
13. Wollenhaupt M, Chandrasekaran A, Tomianovic D. The safety of oseltamivir in pregnancy: an updated review of post-marketing data. *Pharmacoepidemiol Drug Saf*. 2014;23(10):1035-42 (Current impact factor: 2,939)
14. Reinton N, Manley L, Tjade T, Moghaddam A. Respiratory tract infections during the 2011 *Mycoplasma pneumoniae* epidemic. *Eur J Clin Microbiol Infect Dis*. 2013;32(6):835-40 (Current impact factor: 2,668)
15. Jorgensen P, Wasley A, Mereckiene J, et al. Unequal access to vaccines in the WHO European Region during the A (H1N1) influenza pandemic in 2009. *Vaccine*. 2013;31(38):4060-62 (Current impact factor: 3,624)
16. Sturkenboom MC. The narcolepsy-pandemic influenza story: Can the truth ever be unraveled?. *Vaccine*. 2015;33:B6-13 (Current impact factor: 3,624)
17. Durona S, Mayeta A, Lienharda F, et al. The French Military influenza surveillance system (MISS): overview of epidemiological and virological results during four influenza seasons – 2008-2012. *Swiss Med Wkly*. 2013;143:w13848 (Current impact factor: 2,086)
18. Börjesson M, Enander A. Perceptions and sociodemographic factors influencing vaccination uptake and precautionary behaviours in response to the A/H1N1 influenza in Sweden. *Scand J Public Health*. 2014;42(2):215-22 (Current impact factor: 1,832)
19. Baekkeskov E, Rubin O. Why pandemic response is unique: powerful experts and hands-off political leaders. *Disaster Prev Manag*. 2014;23(1):81-93 (Current impact factor: 0,434)
20. Pebody RG, Green HK, Andrews N. Uptake and impact of a new live attenuated influenza vaccine programme in England: early results of a pilot in primary school-age children, 2013/14 influenza season. *Euro Surveill*. 2015;19(22):pii:20823 (Current impact factor: 5,722)
21. Wong VW, Fong DY, Tarrant M. Brief education to increase uptake of influenza vaccine among pregnant women: a study protocol for a randomized controlled trial. *BMC Pregnancy Childbirth*. 2014;14:19 (Current impact factor: 2,190)
22. Determann D, Korfage IJ, Lambooi MS, et al. Acceptance of vaccinations in pandemic outbreaks: a discrete choice experiment. *PloS One*. 2014;9(7):e102505 (Current impact factor: 3,234)
23. Huang WT, Tang FW, Yang SE, et al. Safety of inactivated monovalent pandemic (H1N1) 2009 vaccination during pregnancy: a population-based study in Taiwan. *Vaccine*. 2014;32(48):6463-68 (Current impact factor: 3,624)
24. Supranowicz P, Brydak LB. Opinions of employees of the National Institute of Public Health–National Institute of Hygiene in Warsaw on influenza vaccination. *Przegl Epidemiol*. 2012;67(4):667-74 (SRJ: 0,137)
25. Johansen K. The roles of influenza virus antigens and the AS03 adjuvant in the 2009 pandemic vaccine associated with narcolepsy needs further investigation. *Dev Med Child Neurol*. 2014;56(11):1041-42 (Current impact factor: 3,51)
26. Charland KM, Montigny L, Brownstein JS, Buckeridge DL. Clinic accessibility and clinic-level predictors of the geographic variation in 2009 pandemic influenza vaccine coverage in Montreal, Canada. *Influenza Other Respir Viruses*. 2014;8(3):317-28 (Current impact factor: 2,201)
27. Ahout I, Ferwerda G, de Groot R. Influenza vaccination in kids, are you kidding me? *J Infect*. 2014;68:S100-107 (Current impact factor: 4,441)
28. Laguzet L, Turinici G. Individual vaccination as Nash equilibrium in a SIR model with Application to the 2009-2010 Influenza A (H1N1) Epidemic in France. *Bull Math Biol*. 2015;77(10):1955-84 (Current impact factor: 1,389)
29. Silva ML, Perrier L, Cohen JM, et al. A literature review to identify factors that determine policies for influenza vaccination. *Health Policy*. 2015;119(6):697-708 (Current impact factor: 1,907)
30. Baron-Epel O, Madjar B, Grefat R, Rishpon S. Trust and the demand for autonomy may explain the low rates of immunizations among nurses. *Hum Vaccin Immunother*. 2013;9(1):100-07 (Current impact factor: 2,366)
31. Cloes R, Ahmad A, Reintjes R. Risk communication during the 2009 influenza A (H1N1) pandemic: Stakeholder experiences from eight European countries. *Disaster Med Public Health Prep*. 2015;9(02):127-33 (Current impact factor: 0,696)
32. Atlani-Duault L, Mercier A, Rousseau C, et al. Blood libel rebooted: Traditional scapegoats, online media, and the H1N1 epidemic. *Cult Med Psychiatry*. 2015;39(1):43-61 (Current impact factor: 0,938)
33. Prandoni S. Sudden and fulminant deaths of healthy children in Italy during the 2010-11 and 2011-12 seasons: results of an online study. *J Public Health Res*. 2012;1(2):184 (Nu are factor de impact. Indexat PubMed)
34. Ijnans L, Weibel D, Sturkenboom M. Adjuvanted versus nonadjuvanted influenza vaccines in young children: comparing results from recent clinical trials. *J Clin Invest*. 2013;3(4):395-408 (Current impact factor: 13,261)
35. Jurek T, Rorat M. Adverse event analysis in fatal cases of influenza A (H1N1)—A lesson from Poland. *J Forensic Leg Med*. 2013;20(8):1131-34 (Current impact factor: 0,760)
36. Luteijn JM, Addor MC, Arriola L, et al. The Association of H1N1 Pandemic Influenza with Congenital Anomaly Prevalence in Europe. *Epidemiology*. 2015;26(6):853-61 (Current impact factor: 6,196)
37. Baekkeskov E. Same threat, different responses: experts steering politicians and stakeholders in 2009 H1N1 vaccination policy-making. *Public Administration*. 2016 (Current impact factor: 1,518)
38. Walter D. Bevölkerungsbezogene serielle Querschnittserhebungen zur Impfkampagne gegen die pandemische Influenza in der Saison 2009/10. Doctoral dissertation, Freie Universität Berlin. 2013 (Nu are factor de impact. Este lucrare de dizertație.)
39. Kovács G, Kaló Z, Jahnz-Rozyk K, et al. Medical and economic burden of influenza in the elderly population in central and eastern European countries. *Hum Vaccin Immunother*. 2014;10(2):428-40 (Current impact factor: 2,366)
40. Wahyudi K. Development of a propensity score to handle confounding of the association between H1N1 (2009) pandemic influenza vaccination and the risk of stroke in elderly. 2015 (Nu are factor de impact. Este lucrare de dizertație.)

41. Domínguez A, Godoy P, Torner N. The Effectiveness of Influenza Vaccination in Different Groups. *Expert Rev Vaccines*. 2016;1-14 (Current impact factor: 4,210)
42. Kim MS. Parental characteristics towards child vaccination against pandemic influenza H1N1-2009. HKU Theses Online (HKUTO). 2013
43. Samanlioglu F, Bilge AH. An Overview of the 2009 A (H1N1) Pandemic in Europe: Efficiency of the Vaccination and Healthcare Strategies. (Nu are factor de impact.)
44. Verstraeten T, Cohet C, Dos Santos G, et al. Pandemrix™ and narcolepsy: A critical appraisal of the observational studies. *Hum Vaccin Immunother*. 2015:1-7 (Current impact factor: 2,366)
45. Baekkeskov E, Öberg P. Rally to the Flag Revisited: Freezing Deliberation through Public Expert Advice. Presented at the 2nd International Conference on Public Policy. (Nu are factor de impact.)
46. Pebody RG, Green HK, Andrews N, et al. Uptake and impact of a new live attenuated influenza vaccine programme in England: early results of a pilot in primary school-age children, 2013/14 influenza season. *Euro Surveill*. 2014;19(22).pii:20823 (Current impact factor: 5,722)
47. Green HK. Assessing the epidemiological impact of extending the national influenza vaccination programme to healthy children in England. 2015 (Nu are factor de impact. Este lucrare de doctorat.)
48. Valleron AJ. Can the modeling of herd immunity help design influenza immunization policy?. *Prev Med*. 2012;55(1):78-79 (impact factor: 3,086)
49. Dodd C, Wijmans L, de Ridder M, et al. Pandemic influenza vaccine & narcolepsy: simulations on the potential impact of bias. IN *The Benefits and Risks of Pandemic Influenza Vaccines*. 2015 (Este volum publicat în Olanda, editura Gildeprint, capitolul 7)
50. Atlani-Duault L, Mercier A, Rousseau C, et al. Blood Libel Rebooted: Traditional Scapegoats, Online Media and H1N1 Epidemic. *Cult Med Psychiatry*. 2015;39(1):43-61 (Current impact factor: 0,938)
51. 한눈에, 보는. OECD 보건의료. 2013 Nu are factor de impact.)
52. Wong VL. Background Paper 6.2 Pandemic Influenza. 2013 (Nu are FI)
53. Filipović SK, Gjenero-Margan I, Kissling E, et al. Influenza vaccine effectiveness estimates in Croatia in 2010–2011: a season with predominant circulation of A (H1N1) pdm09 influenza virus. *Epidemiol Infect*. 2015;143(12):2596-603 (Current impact factor: 2,535)
54. Almqvist C, Lundholm C. Population-based data on asthma and allergic disease call for advanced epidemiologic methods. *J Allergy Clin Immunol*. 2015;136(3):656 (Current impact factor: 11,476)
55. Laguzet L. Modélisation mathématique et numérique des comportements sociaux en milieu incertains. Application à l'épidémiologie. Doctoral dissertation, Université Paris-Dauphine. 2015 (Este lucrare de dizertație.)
56. Laguzet L, Turinici G. Individual vaccination as Nash equilibrium in a SIR model: the interplay between individual optimization and societal policies. *Bull Math Biol*. 2015. (Current impact factor: 1,389)

17. Stavri H, Bucurenci N, Ulea I, Costache A, Popa L, **Popa MI**. Use of recombinant purified protein derivative (PPD) antigens as specific skin test for tuberculosis. *Indian J Med Res*. 2012;136:799-807 (Current impact factor: 1.508)

18 citări, citat de: (4)

1. Emmerick LS. Micobactérias não-tuberculosas isoladas da Mata Atlântica aspectos genéticos, bioquímicos e identificação de antígenos compartilhados com a vacina BCG. Instituto Oswaldo Cruz. 2013 (Este teză de dizertație.)
2. Jacobo RG, Serrano CJ, Moreno JE, et al. Analysis of Th1, Th17 and regulatory T cells in tuberculosis case contacts. *Cell Immunol*. 2014;289(1):167-173 (Current impact factor: 3,172)
3. Mitran MI, Gheorghe AS, Tănase AG, Mitran CI. Difficulties in diagnosis and treatment of pulmonary tuberculosis in the elderly. *Infectio.ro*. 2014;39(3):20-23 (Nu are factor de impact. Este indexată BDI.)
4. Stevens GB, Binz T, Römer W, et al. Proteomic analysis of tuberculin purified protein derivatives. *Altex Proceedings*. 2014;3(1/14):201. (Nu are factor de impact. Este carte de abstracte.)
5. Araujo LCT, OTIMIZAÇÃO DO PROCESSO DE PRODUÇÃO DE PROTEÍNAS RECOMBINANTES DE Mycobacterium tuberculosis EM Escherichia coli PARA USO EM DIAGNÓSTICO DE TUBERCULOSE. 2014. (teză de doctorat)
6. Liao M, Liu L, Yang M. Application value of the detection of blood T-SPOT. TB combined with bronchoalveolar lavage fluid (BALF) TbDNA in the diagnosis of tuberculosis. *J Clin Pulm Med*. 2014;19(12):2249-52 (Este indexată BDI)
7. 黄威, 邢益平, 严有德, et al. 种随机引物联合多特异性 DNA 片段检测结核分枝杆菌的新方法. *Progress in Modern Biomedicine*. 2014;(29):5609-16 (Nu are factor de impact.)
8. Yindeeyoungyeon W, Rukseer K, Tungsudjai S, Panichakul T. Evaluation of Recombinant Mycobacterium tuberculosis Antigens MPT64, CFP10, and ESAT6 for Delayed-Type Hypersensitivity Responses in Guinea Pigs. *Adv Microbiol*. 2015;5:586-98 (Este indexată C A)
9. 周利君, 李峰, 卢水华. 以结核分枝杆菌特异性抗原为基础的皮肤试验研究进展. *Chin J Tuberc Respir Dis*. 2015;38(08): 619-622 (Nu are factor de impact.)
10. Thaveekarn W, Pakmanee N, Suntrarachun S, et al. Comparison of specific recombinant proteins to Mycobacterium tuberculosis skin test in animal model. *Int J Pure App Biosci*. 2015;3(1):11-17 (indexată BDI; Nu are factor de impact.)
11. Smith BK. Application of Becton Dickinson FACSTM Combinatorial Antibody Profile (FACSTM CAP) technology to the identification of efficiency of tuberculosis therapy. (2015)
12. Comentador Casal C. Diagnóstico de tuberculosis en rumiantes y camélidos: optimización de pruebas de base celular y humoral. 2016 (teză de doctorat)
13. Moeketsi MR. Functional analysis of the cydC encoded ABC-type transporter in Mycobacterium smegmatis (Doctoral dissertation).
14. Parfeni O, Cristea A. Data on tuberculosis treatment compliance in Harghita county. *Infectio.ro*. 2017;50(2):30-33 (Este indexată BDI)
15. Niño Pedroza CL, Flórez Zapata SV. Satisfacción, seguridad y oportunidad: Características de la atención en salud en Tuberculosis (Doctoral dissertation, Universidad Santiago de Cali). 2018
16. MohanKrishnan A, Patel H, Bhurani V, et al. Inclusion of Non-target antigen in vaccination favors generation of OVA specific CD4 Memory T cells. *Cell Immunol*. 2019;337:1-14. (Current impact factor: 2,995)
17. Dewi DN, Mertaniasih NM, Ozeki Y, et al. Characteristic profile of antibody responses to PPD, ESAT-6, and CFP-10 of Mycobacterium tuberculosis in pulmonary tuberculosis suspected cases in Surabaya, Indonesia. *Braz J Infect Dis*. 2019;23(4):246-53. (Current impact factor: 2,223)
18. Aguilón Durán GP. Genotipificación de Mycobacterium tuberculosis mediante MIRU-VNTR 24 loci. 2019 (teza de doctorat)

18. Zaharia DC, Muntean A, Popa MG, Steriade A, Balint O, Micut R, Iftene C, Tofolean I, Popa VT, Baicus C, Bogdan MA, **Popa MI**. Comparative analysis of Staphylococcus aureus and Escherichia coli microcalorimetric growth. *BMC Microbiol*. 2013;13:171 (Current impact factor: 2,829)

18 citări, citat de: (12)

1. Zaharia DC, Popa MG, Steriade AT, et al. Microcalorimetry a new method for bacterial characterisation. *Pneumologia*. 2013;62(4):232-235. (Este indexată BDI)
2. Mariana F. Chip-Calorimetric Monitoring and Biothermodynamic Analysis of Biofilm Growth and Interactions with Chemical and Biological Agents. Fakultät Maschinenwesen der Technischen Universität Dresden. 2014. (doctorat.)
3. Braissant O, Keiser J, Meister I, et al. Isothermal microcalorimetry accurately detects bacteria, tumorous microtissues, and parasitic worms in a label-free well-plate assay. *Biotechnol J*. 2015;10(3):460-468 (Current impact factor: 3,649)
4. Staicu T, Cîrcu V, Ioniță G, et al. Analysis of bimodal thermally-induced denaturation of type I collagen extracted from calfskin. *RSC Advances*. 2015;5(48):38391-406 (Current impact factor: 3,108)

5. Braissant O, Bachmann A, Bonkat G. Microcalorimetric assays for measuring cell growth and metabolic activity: methodology and applications. *Methods*. 2015;76:27-34 (Current impact factor: 3,802)
 6. Fredua-Agyeman M. The application of isothermal microcalorimetry for studying mixed probiotic cultures. UCL School of Pharmacy. 2015. (Nu are factor de impact. Este lucrare de doctorat. Doctoral dissertation, UCL (University College London).
 7. Wu M, Qu F, Zhao Y, et al. Microcalorimetry and turbidimetry to investigate the anti-bacterial activities of five fractions from the leaves of *Dracontomelon dao* on *P. aeruginosa*. *J Thermal Anal Calorim*. 2016;123:2367-76 (Current impact factor: 1,953)
 8. Precupas A, Sandu R, Popa V. Quercetin Influence on Thermal Denaturation of Bovine Serum Albumin. *J Phys Chem B*, 2016;120(35):9362-9375 (Current impact factor: 3,177)
 9. Bastos Margarida. Biocalorimetry: Foundations and Contemporary Approaches. Ed. CRC Press, Taylor and Francis Group. 2016 (este carte)
 10. Moldoveni care au scris în limba rusă: Сравнительный анализ параметров дифференциальных термограмм популяций *E. coli*, *S. Aurea*, *P. Aeruginosa*, *C. Albicans* с позиции ускоренного их ... AI Дραπεза, ГА Скороход, ЕИ Гудкова, ВА Лобан... - 2017 - rep.bsmu.by Comparative analysis of the parameters of different types differential thermogram microorganisms *E. coli*, *S. aureus*, *P. aeruginosa* and *C. albicans* from the position of accelerated their detection and differentiation. A. I. Drapeza, G. A. Chkhorhod, E. I. Gudkova, V. A. Loban, N. V. Pleshko
 11. Muwaffak Z, Goyanes A, Clark V, Basit AW, Hilton ST, Gaisford S. Patient-specific 3D scanned and 3D printed antimicrobial polycaprolactone wound dressings. *Intern J Pharmaceutics*. 2017;527(1):161-70. (Current impact factor: 3,649)
 12. Sokhadze VM, Namchevadze EN, Kiziria EN, et al. The study of time-course toxic impact of Ni on the thermostability of the soil *Arthrobacter oxydans* bacterial cell culture. *Annals Agrar Sci*. 2017;15(2):169-176 (este BDI)
 13. Klodzinska SN, Priemel PA, Rades T, Nielsen HM. Combining diagnostic methods for antimicrobial susceptibility testing—A comparative approach *J Microbiol Methods*. 2017;144:177-185. (Current impact factor: 1,79)
 14. Popa M, Ene R, Streinu-Cercel A, et al. Algic Syndrome in Osteoarticular Infectious Pathology; Detection and Rapid Treatment of the Causative Agent Using Microcalorimetry. Proceedings of The 14th National Congress of Urogynecology (7-9 September 2017) and of The National Conference of The Romanian Association for the study of pain (26-27 October 2017), Bucharest. Filodiritto Publisher. 2017:589-594 (Indexat Clarivate Analytics)
 15. Tsuchiya K, Cao YY, Kurokawa M, et al. A decay effect of the growth rate associated with genome reduction in *Escherichia coli*. *BMC Microbiol*. 2018;18(1):101-109. (Current impact factor: 2,829)
 16. Precupas A, Leonties AR, Neacsu A, et al. Gallic acid influence on bovine serum albumin thermal stability. *New J Chemistry*. 2019;43(9):3891:3898. (Current Impact Factor: 3,201)
 17. Fricke C, Harms H, Maskow T. Rapid Calorimetric Detection of Bacterial Contamination: Influence of the Cultivation Technique. *Front Microbiol*. 2019;10:2530. (Current impact factor: 4,259)
 18. Lemos D, Oliveira T, Martins L, et al. Isothermal Microcalorimetry of Tumor Cells: Enhanced Thermogenesis by Metastatic Cells. *Front Oncol*. 2019;18(9):1430. (Current impact factor: 4,137).
19. Popa GL, Tanase I, Popa CA, Mastalier B, Popa MI, Cretu CM. Medical and surgical management of a rare and complicated case of multivisceral hydatidosis; 18 years of evolution. *New Microbiol*. 2014;37(3):387-391 (Current impact factor: 1,412)
- 2 citări, citat de (1):
1. Rodriguez-Morales AJ, Calvo-Betancourt LS, Alarcón-Olave C, Bolívar-Mejía A. Echinococcosis in Colombia - A Neglected Zoonosis? (In book: Current Topics in Echinococcosis, Edition: 1st, Chapter: 1, Publisher: InTech, pp.3-30). 2015 (Nu are factor de impact. Este carte.)
 2. Zouari M, Abdallah AK, Ammar S, Mhiri R. Multivisceral Hydatidosis in a 5-Year-Old Boy. *Iran J Med Sci*. 2018;43(3):340-341. (este indexată C A, fara FI)
20. Mihai MM, Holban AM, Giurcăneanu C, Popa LG, Buzea M, Filipov M, Lazăr V, Chifiriuc MC, Popa MI. Identification and phenotypic characterization of the most frequent bacterial etiologies in chronic skin ulcers. *Rom J Morphol Embryol*. 2014;55(4):1401-8 (Current impact factor: 0.912)
- 34 citări, citat de: (25) (+ 2 autocitări)
1. Baumann A, Lehmann R, Beckert A, et al. Selection and evaluation of tissue specific reference genes in *Lucilia sericata* during an immune challenge. *PLoS One*. 2015;10(8):e0135093 (Current impact factor: 2,806)
 2. Ionescu B, Ionescu D, Gheorghe I, et al. Virulence patterns of *Staphylococcus aureus* hospital strains isolated in Bucharest, Romania. *Rom Biotech Lett*. 2015;20(3):10536-46 (Current impact factor: 0,396)
 3. Mihai MM, Holban AM, Giurcăneanu C, et al. Microbial biofilms: impact on the pathogenesis of periodontitis, cystic fibrosis, chronic wounds and medical device-related infections. *Curr Top Med Chem*. 2015;15(16):1552-76 (Current IF: 3,402)
 4. Mihai MM, Giurcăneanu C, Popa LG, et al. Controversies and challenges of chronic wound infection diagnosis and treatment. *Mod Med*. 2015;22(4):375-381 (Este indexată BDI.)
 5. Tutelyan AV, Gaponov AM, Pisarev VM, El-Registan GI. Microbial dormancy and prevention of healthcare-associated infections. *Terapevticheski Arkhiv*. 2015;87(11):103-8. (Current impact factor: 0,247).
 6. Georgescu M, Gheorghe I, Curutiu C, et al. Virulence and resistance features of *Pseudomonas aeruginosa* strains isolated from chronic leg ulcers. *BMC Infect Dis*. 2016;16(Suppl 1):92 (Current impact factor: 2,768)
 7. Porumbel I, Gheorghe I, Popa M, et al. Virulence and resistance genes profiles among *Pseudomonas aeruginosa* isolated in 2015 from patients with cardiovascular diseases in Bucharest, Romania. *Biointerface Res Appl Chem*. 2016;6(2):1176-1179. (indexată C A)
 8. de Oliveira FP, Chrizóstimo MM, Barreto BM, da Silva E. Ação antimicrobiana do fator de crescimento epidérmico em feridas: revisão integrativa. *Revista Enfermagem Atual In Derme*. 2016; 78
 9. Ярец ЮИ. Острый и хронический раневой процесс: патогенетические особенности. Медико-биологические проблемы жизнедеятельности. 2016(2):21-34.
 10. Merezeanu N, Gheorghe I, Popa M, et al. Virulence and resistance features of *Pseudomonas aeruginosa* strains isolated from patients with cardiovascular diseases. *Biointerface Res Appl Chem*. 2016;6(2): 1117-1121 (este indexată C A) (indexată BDI, nu are factor de impact)
 11. Acevedo F, Torres P, Oomah BD, et al. Volatile and non-volatile/semi-volatile compounds and *in vitro* bioactive properties of Chilean Ulmo (*Eucryphia cordifolia* Cav.) honey. *Food Res Int*. 2017;94:20-28 (Current impact factor: 3,086)
 12. Zautner AE, Groß U, Emele MF, Hagen RM, Frickmann H. More Pathogenicity or Just More Pathogens? - On the Interpretation Problem of Multiple Pathogen Detections with Diagnostic Multiplex Assays. *Frontiers Microbiol*. 2017;29:8:1210. (Current impact factor: 4,076)
 13. Baumann A. probail teză de doctorat GEB - Giessener Elektronische Bibliothek. New tools for maggot debridement therapy research: From the establishment of qRT-PCR to the characterization of *Lucilia sericata* Urate Oxidase Baumann, Andre Zum Volltext im pdf-Format: Dokument 1.pdf (8.959 KB), 2017
 14. Grigore ME, Grumezescu AM, Holban AM, Mogoșanu GD, Andronescu E. Collagen-Nanoparticles Composites for Wound Healing and Infection Control *Metals*. 2017;23;7(12):516 (Current impact factor: 1,984)
 15. de Oliveira FP, Pires BM, de Almeida KD, et al. Prevalence, Antimicrobial Susceptibility, and Clonal Diversity of *Pseudomonas aeruginosa* in Chronic Wounds. *J Wound Ostomy Continence Nursing*. 2017;44(6):528-35 (Current IF: 1,586)
 16. Aloe CM, Enhancing Wound Repair with Marine Natural Products and Nanoparticles, teză de doctorat, 2017(august), 217 pagini
 17. Sadik O, Ditu LM, Gheorghe I, et al. Adherence and Biofilm Formation in *Candida albicans* Strains Isolated from Different Infection Sites in Hospitalized Patients. *Rev Chim (Bucharest)*. 2017;68(12):2832-2835 (Current Impact Factor: 1,232)

18. Mitache MM, Curutiu C, Rusu E, et al. Urinary Tract Infections in Patients with Type 1 and Type 2 Diabetes: Etiology, Resistance to Antibacterial Chemicals and Virulence Features. *Rev Chim.* 2017;68(3):566-9. (Current impact factor: 1,412).
 19. Tatu LA, Merezeanu N, Pantea O, et al. Resistance features of *Pseudomonas aeruginosa* strains isolated from patients with infectious complications of cardiovascular surgery. *Biointerface Res Appl Chem.* 2017;7(2):2004-2008 (indexata CA)
 20. Curutiu C, Ditu LM, Iordache F, et al. Quorum Sensing molecules produced by *Pseudomonas aeruginosa* impair attachment and biofilm formation in *Candida albicans*. *Biointerface Res Appl Chem.* 2017;7(2):2016-2020. (indexata CA)
 21. Negut I, Grumezescu V, Grumezescu A. Treatment Strategies for Infected Wounds. *Molecules.* 2018;23(9):E2392. (Current impact factor: 3,098)
 22. Waite RD, Stewart JE, Stephen AS, Allaker RP. Activity of a Nitric Oxide Generating Wound Treatment System against Wound Pathogen Biofilms. *Int J Antimicrob Agents.* 2018;52(3):338-343. (Current impact factor: 4,253)
 23. Pires BM, de Oliveira FP, de Oliveira BG, et al. Monitoring and Molecular Characterization of *Staphylococcus aureus* Isolated from Chronic Wounds. *Adv Skin Wound Care.* 2018;31(9):399-405. (Current impact factor: 1,377)
 24. Deutsch G, de Castilho SR. Treatment of diabetic ulcers with epidermal growth factor. *Revista Enfermagem Atual.* 2018;85 (Este indexata BDI).
 25. Mihai MM, Preda M, Lungu I, Gestal MC, Popa MI, Holban AM. Nanocoatings for Chronic Wound Repair - Modulation of Microbial Colonization and Biofilm Formation. *Int J Mol Sciences.* 2018;19(4):1179. (Current impact factor: 3,687)
 26. Dogan-Guner EM, Mohamed H, Orbey N, Goodyear N. Stabilization and Controlled Release of Microencapsulated Hydrogen Peroxide for Wound Treatment Applications. *J Appl Microbiol.* 2019;126(3):965-972. (Current impact factor: 2,16)
 27. Mitache MM, Curutiu C, Gheorghe I, et al. Phenotypic, Biochemical and Genotypic Characterisation of Some Factors Involved in the Virulence and Survival of Bacteria Isolated from Food and Food Processing Surfaces. *Rev Chim.* 2018;69(1):116-20 (Current impact factor: 1,412).
 28. Haalboom M. Chronic Wounds: Innovations in Diagnostics and Therapeutics. *Curr Med Chem.* 2018;25(41):5772-5781. (Impact Factor: 3,894).
 29. Ferro TA, Souza EB, Suarez MA, et al. Topical Application of Cinnamaldehyde Promotes Faster Healing of Skin Wounds Infected with *Pseudomonas aeruginosa*. *Molecules.* 2019;24(8):1627 (Current impact factor: 3,09).
 30. Ruffin M, Brochiero E. Repair Process Impairment by *Pseudomonas aeruginosa* in Epithelial Tissues: Major Features and Potential Therapeutic Avenues. *Front Cell Infect Microbiol.* 2019;9:182. (Current impact factor: 3,09).
 31. Mihai MM, Dima MB, Dima B, Holban AM. Nanomaterials for Wound Healing and Infection Control. *Materials (Basel).* 2019;12(13). (IF: 2,972).
 32. De Oliveira, Beatriz GRB, et al. Epidermal growth factor vs platelet-rich plasma: Activity against chronic wound microbiota. *Int Wound J.* 2019. DOI: 10.1111/iwj.13205 (Current impact factor: 2,385).
 33. Fuss J, Voloboyeva A. Differentiated usage of ointments in the treatment of infected wounds. *Infection.* 2019;47: S59-S59 (IF: 2,927)
 34. Mahmood YS, Abed SM, Alwan AM. Isolation, Identification of bacterial species causing chronic suppurative otitis media and detection some of their virulence factors. *Tikrit Journal of Pure Science,* 2019;24(7):45-51 (este BDI)
 21. Mihai MM, Holban AM, Giurcăneanu C, Popa LG, Oanea RM, Lazar V, Chifiriuc MC, Popa M, **Popa MI.** Microbial biofilms: impact on the pathogenesis of periodontitis, cystic fibrosis, chronic wounds and medical device-related infections. *Curr Top Med Chem.* 2015;15(16):1552-76 (premiu **PN-II-RU-PRECISI-2015-9-10117**) (Current impact factor: 3,374)
- 52 citări, citat de: (38) +(1 autocitare)**
1. Mihai MM, Giurcăneanu C, Popa LG, et al. Controversies and challenges of chronic wound infection diagnosis and treatment. *Mod Med.* 2015;22(4):375-381 (Nu are factor de impact. Este indexată BDI.)
 2. Vartoukian SR, Adamowska A, Lawlor M, et al. In Vitro Cultivation of 'Unculturable' Oral Bacteria, Facilitated by Community Culture and Media Supplementation with Siderophores. *PLoS One.* 2016;11(1):e0146926 (Current impact factor: 2,806)
 3. Melvin JA, Montelaro RC, Bomberger JM. Clinical potential of engineered cationic antimicrobial peptides against drug resistant biofilms. *Exp Rev Anti-Inf Therapy.* 2016;14(11): 989-991 (citează la nr. 1) (Current impact factor: 3,139)
 4. Vartoukian SR, Moazzez RV, Paster BJ, et al. First Cultivation of Health-Associated *Tannerella* sp. HOT-286 (BU063). *J Dent Res.* 2016;95(11):1308-13 (Current impact factor: 4,755)
 5. Solomon I, Giurcăneanu C, Pop LG, Mihai MM. Patogeneza infecțioasă și antibioterapia hidradenitei supurative. *Infectio.ro.* 2016;46:28-32.
 6. Vartoukian SR. Cultivation strategies for growth of uncultivated bacteria *J Oral Biosciences.* 2016;58(4):143-149 (CA fara IF)
 7. Maura D, Ballok AE, Rahme LG. Considerations and caveats in anti-virulence drug development. *Current Opinion Microbiol.* 2016;33:41-46 (IF: 6,635)
 8. Lira RMM, Limón Flores AY, Salinas Carmona MC, Ortiz Stern A. Experimental Granulomatous Pulmonary Nocardiosis in BALB/C Mice. *PLoS ONE.* 2016;11(6): e0157475. (Current impact factor: 2,806)
 9. Holban A, Vlad M, Grumezescu V, et al. Impact of alginate on the biocompatibility of magnetite nanoparticles utilized for drug delivery. *UPB Scientific Bulletin, Series B.* 2016;78(4):41-52
 10. Dhom J, Bloes DA, Peschel A, Hofmann UK. Bacterial adhesion to suture material in a contaminated wound model: Comparison of monofilament, braided, and barbed sutures. *J. Orthop Res.* 2017;35(4):925-933 (Current impact factor: 2,692)
 11. Stoica P, Chifiriuc MC, Rapa M, et al. Overview of biofilm-related problems in medical devices ... - Biofilms and Implantable (carte internațională) 2017
 12. Fleming D, Chahin L, Rumbaugh K. Glycoside Hydrolases Degrade Polymicrobial Bacterial Biofilms in Wounds. *Antimicrob Agents Chemother.* 2017;61(2). pii: e01998-16. (Current impact factor: 4,302)
 13. Zhang J, Cheah YS, Santhanakrishnan S et al. Methoxy group substitution on catechol ring of dopamine facilitates its polymerization and formation of surface coatings. *Polymer.* 2017;116:5-15 (Current impact factor: 3,684)
 14. Omer H, McDowell A, Alexeyev OA. Understanding the role of *Propionibacterium acnes* in acne vulgaris: the critical importance of skin sampling methodologies. *Clin Dermatol.* 2017;35(2):118-129 (citează la nr. 96) (Current impact factor: 2,253)
 15. Francolini I, Vuotto C, Piozzi A, Donelli G. Antifouling and antimicrobial biomaterials: an overview. *Acta Path Microbiol Immunol Scand.* 2017;125(4):392-417 (Current impact factor: 1,795)
 16. Ellis JE, Richard Heuser R, Missan DS, et al. Evidence for polymicrobial communities in explanted vascular filters and atheroma debris. *Mol Cell Probes.* 2017;33:65-77. (Current impact factor: 1,403)
 17. Hughes G, Webber MA. Novel approaches to the treatment of bacterial biofilm infections. *Br J Pharmacol.* 2017;174(14):2237-2246 (IF: 5,491)
 18. Gonzalez Moreno M, Lombardi L, Di Luca M. Antimicrobial Peptides for the Control of Biofilm Formation. *Curr Top Med Chem.* 2017;17(17):1965-86. (Current impact factor: 2,561)
 19. Zautner AE, Groß U, Emele MF, Hagen RM, Frickmann H. More Pathogenicity or Just More Pathogens?—On the Interpretation Problem of Multiple Pathogen Detections with Diagnostic Multiplex Assays. *Front Microbiol.* 2017;8:1210. (Current impact factor: 4,076)
 20. Martinez-Rivera JI, Xibillé-Friedmann DX, Gonzalez-Christen J, Garza-Ramos MA, Carrillo-Vazquez SM, Montiel-Hernandez JL. Salivary ammonia levels and *Tannerella forsythia* are associated with rheumatoid arthritis: A cross sectional study. *Clin Exp Dent Res.* 2017;3:107-114 (indexată CA)
 21. Grigore ME, Grumezescu AM, Holban AM, Mogoșanu GD, Andronesu E. Collagen-Nanoparticles Composites for Wound Healing and Infection Control. *Metals.* 2017;23;7(12):516 (Current impact factor: 1,984)
 22. Cai Y, Wang J, Liu X, et al. A Review of the Combination Therapy of Low Frequency Ultrasound with Antibiotics. *BioMed Res Int.* 2017;2017:2317846. (Current impact factor: 2,476)
 23. Soavelomandroso AP, Gaudin F, Hoys S, et al. Biofilm Structures in a Mono-Associated Mouse Model of *Clostridium difficile* Infection. *Frontiers Microbiol.* 2017;8:2086. (Current impact factor: 4,076)
 24. Shrestha CL, Assani KD, Rinehardt H, et al. Cysteamine-mediated clearance of antibiotic-resistant pathogens in human cystic fibrosis macrophages. *PLoS One.* 2017;12(10): e0186169. (Current impact factor: 2,806)

25. Jiang YL, Qiu W, Zhou XD, et al. Quaternary ammonium-induced multidrug tolerant *Streptococcus mutans* persists elevate cariogenic virulence in vitro. *Int J Oral Science*. 2017;9(12): e7 (Current impact factor: 3,93)
26. 邢磊, et al. 未培养微生物分离培养技术研究进展. *微生物学通报*. 2017;44(12):3053-3066. (este BDI)
27. 关统伟, et al. 硝尔库勒湖可培养放线菌多样性及其功能酶和抗菌活性. *微生物学报*. 2018;58(10):1864-1874. (este BDI)
28. Malheiro J, Simoes M. Antimicrobial resistance of biofilms in medical devices. In *Biofilms and Implantable Medical Devices 2017* (pp. 97-113). (carte internationala)
29. Bahamondez-Canas T, Smyth HD. Influence of Excipients on the Antimicrobial Activity of Tobramycin Against *Pseudomonas aeruginosa* Biofilms. *Pharm Res*. 2018;35(1):10 (Current Impact factor: 3,002)
30. Wang L, Keatch R, Zhao Q, et al. Influence of type-I fimbriae and fluid shear stress on bacterial behavior and multicellular architecture of early *Escherichia coli* biofilms at single-cell resolution. *Appl Environ Microbiol*. 2018 Mar 1;84(6). pii: e02343-17. (Current impact factor: 3,807)
31. Pandit S, Cao Z, Mokkapat V. Vertically Aligned Graphene Coating is Bactericidal and Prevents the Formation of Bacterial Biofilms. *Adv Mater Interfaces*. 2018;1701331 (Current impact factor: 4,279)
32. Magana M, Sereti C, Ioannidis A, et al. Options and Limitations in Clinical Investigation of Bacterial Biofilms. *Clin Microbiol Rev*. 2018;31(3). pii: e00084-16. (Current Impact Factor: 19,958)
33. Patt MW, Conte L, Blaha M, Plotkin BJ. Steroid hormones as interkingdom signaling molecules: Innate immune function and microbial colonization modulation. *AIMS Molecular Science*. 2018. 5(1): 117-130 (indexata CA).
34. Dima B, Mihai MM, Popa LG, et al. The role of bacterial colonization in the pathophysiology of hidradenitis suppurativa. *Infectio.ro*. 2018;53(1):5-9.
35. Arnold MR, Kao AM, Gbozah KK, et al. Optimal management of mesh infection: Evidence and treatment options. *Int J Abd Wall Hernia Surgery*. 2018;1(2):42. (indexata BDI)
36. D'Abrosca G, Paladino A, Cuoco E et al. Structural Characterization of the *Lactobacillus Plantarum* FlmC Protein Involved in Biofilm Formation. *Molecules*. 2018;23(9):E2252 (Current impact factor: 3,098).
37. Wiesenmueller S, Cierniak P, Juebner M, et al. Tailored antimicrobial activity and long-term cytocompatibility of plasma polymer silver nanocomposites. *J Biomater Appl*. 2018;33(3):327-339. (Current impact factor: 2,082)
38. Coakley KM, Heniford BT, Augenstein VA. Abdominal Wall Mesh Infections. In *Management of Abdominal Hernias 2018* (pp. 511-518). Springer, Cham. (este carte)
39. Bahamondez-Canas TF, Ferrati S, Moraga-Espinoza DF, Smyth HD. Development, characterization, and in vitro testing of co-delivered antimicrobial dry powder formulation for the treatment of *Pseudomonas aeruginosa* biofilms. *J Pharm Sci*. 2018;107(8):2172-2178. (Current impact factor: 3,075)
40. Bahamondez-Canas TF, Zhang H, Tewes F, Leal J, Smyth HD. PEGylation of tobramycin improves mucus penetration and antimicrobial activity against *Pseudomonas aeruginosa* biofilms in vitro. *Mol Pharm*. 2018;15(4):1643-1652. (Current impact factor: 4,556)
41. Lintzeris D, Vernon K, Percise H, Strickland A, Yarrow K, White A, Gurganus M, Sherrod S, Vergin K, Johnson L. Effect of a New Purified Collagen Matrix With Polyhexamethylene Biguanide on Recalcitrant Wounds of Various Etiologies: A Case Series. *Wounds: a compendium of clinical research and practice*. 2018;30(3):72-8. (Current impact factor: 1,593).
42. Mihai MM, Preda M, Lungu I, et al. Nanocoatings for Chronic Wound Repair - Modulation of Microbial Colonization and Biofilm Formation. *Int J Mol Sciences*. 2018;19(4):1179. (Current impact factor: 3,687).
43. Rivolo M. Periodontal-disease-and-chronic-wounds-the-theory-of-wound-focal-infection-in-a-modern-context. *Wounds Int*. 2019;10(1):28-31. (este BDI)
44. Casal D, Iria I, Ramalho JS et al. BD-2 and BD-3 increase skin flap survival in a model of ischemia and *Pseudomonas aeruginosa* infection. *Sci Rep*. 2019;9(1):7854. (Current impact factor: 4,122).
45. Baishya J, Wakeman CA. Selective pressures during chronic infection drive microbial competition and cooperation. *NPJ Biofilms and Microbiomes*. 2019;5(1):1-16. (Current impact factor: 4,128).
46. Mihai MM, Dima MB, Dima B, Holban AM. Nanomaterials for Wound Healing and Infection Control. *Materials (Basel)*. 2019;12(13). (IF: 2,972).
47. Oropallo AR. Use of Native Type I Collagen Matrix Plus Polyhexamethylene Biguanide for Chronic Wound Treatment. *Plast Reconstr Surg Glob Open*. 2019;7(1):e2047 (este BDI).
48. Patel DR, Bhartiya SK, Kumar R, et al. Use of Customized Bacteriophages in the Treatment of Chronic Nonhealing Wounds: A Prospective Study. *Int J Low Extrem Wounds*. 2019;1534734619881076. (Current impact factor: 1,277).
49. Francolini I, Piozzi A. Role of Antioxidant Molecules and Polymers in Prevention of Bacterial Growth and Biofilm Formation. *Curr Med Chem*. 2019. doi: 10.2174/0929867326666190409120409. (Current impact factor: 3,894).
50. Li L, Wang Y, Zhang B, et al. Superhydrophilic coating platform supported synergistic antimicrobial ability for enhanced wound healing. *SSRN Electronic Journal*. 2019;3493849 (este BDI)
51. Choi W, Jin J, Park S et al. Quantitative Interpretation of Hydration Dynamics Enabled the Fabrication of a Zwitterionic Antifouling Surface. *ACS Appl Mater Interfaces*. 2020;12(7):7951-7965. (Current impact factor: 8,456).
52. Wang Y, Hoffmann JP, Chou CW. *Burkholderia thailandensis* outer membrane vesicles exert antimicrobial activity against drug-resistant and competitor microbial species. *J Microbiol*. 2020. doi: 10.1007/s12275-020-0028-1. (Current impact factor: 2,319)
22. Neagu AC, Chifiriuc MC, Săndulescu O, Streinu-Cercel A, Oprea M, Drăgulescu EC, Gheorghe I, Berciu I, Bleotu C, Popa M, Oțelea D, Tălăpan D, Dorobăț O, Codiță I, **Popa MI**, Streinu-Cercel A. Bacteriophage-driven inhibition of biofilm formation in *Staphylococcus* strains from patients attending a Romanian reference center for infectious diseases. *FEMS Microbiol Lett*. 2016 Aug 11. pii: fnw193. [Epub ahead of print] ISI (Current impact factor: 1,735)
- 7 citări, citat de: (2)
1. Reid G. Probiotic use in an infectious disease setting. *Exp Rev Anti-Inf Therapy*. 2017;2017;15(5):449-455 (Current impact factor: 3,139)
2. Săndulescu O, Săndulescu M. (2017) Anti-biofilm Agents. In: *Recent Clinical Techniques, Results, and Research in Wounds*. Springer, Cham doi.org/10.1007/15695_2017_4
3. Fu Li-na; Wang Li-li; Li Xiao-yu; et al. Advances in phage control of three drug-resistant strains. *Zhongguo Kangshengsu Zazhi*. 2017;42(10):836-841. (indexata BDI).
4. Qu Kun-li, Cong Cong, Wang Li-li et al. Research progress on biofilm destruction by bacteriophages. *Zhongguo Kangshengsu Zazhi*. 2017;42(10):849-857. (este indexata BDI)
5. Wermser C. Morphology, regulation and interstrain interactions in a new macrocolony biofilm model of the human pathogen, *Staphylococcus aureus*. 2019. (teza de dizertatie)
6. Săndulescu O, Săndulescu M. Anti-biofilm Agents. *Biofilm, Pilonidal Cysts and Sinuses*. 2020:27-54. (este BDI).
7. Cepko LCS, Garling EE, Dinsdale MJ. Myoviridae phage PDX kills enteroaggregative *Escherichia coli* without human microbiome dysbiosis. *J Med Microbiol*. 2020;69(2):309-323. (Current journal impact factor: 1,926).
23. Cristea CV, Gheorghe I, Neacsu G, Galca R, Czobor I, Alexandru I, Chifiriuc MC, Lazar V, **Popa MI**. *Staphylococcus* spp Involvement in Community Acquired Urinary Tract Infections. *Rom Biotech Letters*. 2016;21(2):11413-417 (Current impact factor: 0,321)
- 1 citare, citat de: (1)
1. Porumbel I, Chelariu M, Gheorghe I, et al. Genotypic characterization of virulence and resistance markers in ESBL positive *Escherichia coli* strains isolated from ambulatory urinary tract infections. *Rom Biotech Letters*. 2018;23(3):13572-80. (Current impact factor: 0,321).
24. Neagu AC, Streinu-Cercel A, Săndulescu O, Moțoi MM, Berciu I, **Popa MI**, Streinu-Cercel A. Bacteriophages – novel biotechnology tools available in clinical practice in Romania. *Rom Biotech Letters*. 2017;22(2):12492-495 (factor de impact 0,404) (Current impact factor: 0,321)

2 citari, citat de:

1. Săndulescu O, Săndulescu M. (2017) Anti-biofilm Agents. In: Recent Clinical Techniques, Results, and Research in Wounds. Springer, Cham doi.org/10.1007/15695_2017_4

2. Săndulescu O, Săndulescu M. Anti-biofilm Agents. Biofilm, Pilonidal Cysts and Sinuses. 2020;27-54. (este BDI)

25. Dragomirescu CC, Lixandru BE, Coldea IL, Palade AM, Baltoiu M, Dinu S, Cristea CV, Manolescu L, **Popa MI**. Comparative analysis of different phenotypic and molecular methods used for the taxonomic identification of *Corynebacterium* spp. isolated from clinical samples in Romania. Rom Biotech Letters. 2017;22(5):12926-933 (FI: 0.321).

2 citari, citat de (1) + (1):

1. Popa M, Ene R, Streinu-Cercel A, et al. Algic Syndrome in Osteoarticular Infectious Pathology; Detection and Rapid Treatment of the Causative Agent Using Microcalorimetry. Proceedings of The 14th National Congress of Urogynecology (7-9 September 2017) and of The National Conference of The Romanian Association for the study of pain (26-27 October 2017), Bucharest. Filodiritto Publisher. 2017:589-594 (Indexat Clarivate Analytics)

2. Dragomirescu CC, Lixandru BE, Coldea IL, et al. Antimicrobial Susceptibility Testing for *Corynebacterium* Species Isolated from Clinical Samples in Romania Antibiotics (Basel). 2020;9(1):31. (Current impact factor: 2.921)

26. Peneş N, Muntean AA, Moisoiu A, Muntean MM, Chirca A, Bogdan MA, **Popa MI**. An overview of resistance profiles ESKAPE pathogens from 2010-2015 in a tertiary respiratory center in Romania. Rom J Morphol Embryol. 2017;58(3):909-922 (FI 0,912)

10 citari, citat de (4):

1. Hagen K. A review of bacteriophage therapy for *Pseudomonas aeruginosa* infections (Doctoral dissertation). 2018

2. Calva Salas JL. Estudio de infecciones por gérmenes multiresistentes en pacientes con y sin inmunocompromiso, en el Hospital Pediátrico Baca Ortiz, 2017 (Master's thesis, Quito: UCE). (teza de doctorat)

3. 李楠, 张豪杰, 王悦, 祁萌, 郭文学, 王哲, 祁伟. TEM-1 型 β -内酰胺酶及 CarO 蛋白介导的耐舒巴坦鲍曼不动杆菌临床株耐药机制研究. 天津医药. 2018 Mar 23(3):246-50.

4. Unver E, Karakecili F, Cikman A. Assessment of Viral and Atypical Bacterial Agents Using Polymerase Chain Reaction in Patients Presenting with Signs of Acute Respiratory Tract Infection. West Ind Med J. 2018;67(4). (Current impact factor: 0,224)

5. Li Nan, ZHANG Hao-jie, WANG Yue, et al. Study on the drug resistance of clinical strain of *acinetobacter baumannii* mediated by TEM-1 beta-lactamases and porin CarO. Tianjin Med J. 2018;46(3):246-250. (este BDI).

6. Докторска дисертација. ФАРМАКОТЕРАПИЈСКИ ПРОТОКОЛИ ЗА ПРИМЕНУ АНТИБИОТИКА У ХИРУРШКОЈ ЈЕДИНИЦИ ИНТЕНЗИВНЕ ТЕРАПИЈЕ. Нови Сад, 2018. Године (teza de dizertatie)

7. Zaha DC, Bungau S, Alea S, et al. What antibiotics for what pathogens? The sensitivity spectrum of isolated strains in an intensive care unit. Sci Total Environ. 2019;687:118-127. (Current Impact Factor: 5,589).

8. Popa M, Ene R, Streinu-Cercel A, et al. Algic Syndrome in Osteoarticular Infectious Pathology; Detection and Rapid Treatment of the Causative Agent Using Microcalorimetry. Proceedings of the 14th National Congress of Urogynecology (7-9 September 2017) and of The National Conference of the Romanian Association for the study of pain (26-27 October 2017), Bucharest. Filodiritto Publisher. 2017:589-594 (Indexat Clarivate Analytics)

9. Chen X, Lou W, Liu J, et al. A novel antimicrobial polymer efficiently treats multidrug-resistant MRSA-induced bloodstream infection. Bioscience reports. 2019;39(10). (Current impact factor: 2,535).

10. Coker M, Onu E. Antibacterial and Antiadherence Properties of the Leaves of *Ficus Thoningii* Blume on *Acinetobacter Baumannii*. Nig J Pharma Res. 2020;15(2):193-204.(Este BDI).

27. Muntean MM, Muntean AA, Gauthier L, Creton E, Cotellon G, **Popa MI**, Bonnin R, Naas T. Evaluation of the Rapid Carbapenem Inactivation Method (rCIM): a phenotypic screening test for carbapenemase producing Enterobacteriaceae. J Antimicrobial Chemotherapy. 2018;73(4):900-908 ISI (FI 5.217)

14 citari (2 autocitari), citat de (11):

1. Muntean AA, Poenaru A, Neagu A, Caracoti C, Muntean MM, Popa VT, Bogdan MA, Naas T, Popa MI. Use of the Rapid Carbapenem inactivation method (rCIM) with Carbapenemase inhibitors: a pRoof of ConCept experiment. Rom Arch of Microbiol Immunol. 2018;77(1):50-7. (autocitare)

2. Thierry Naas. Letter to the editor. Rom Arch Microbiol Immunol. 2018;77(1):84-85. (Este indexata BDI) (autocitare)

3. Uechi K, Tada T, Kuwahara-Arai K, Sekiguchi JI, Yanagisawa I, Tome T, Nakasone I, Maeda S, Mya S, Zan KN, Tin HH. An improved carbapenem inactivation method, CIMTrisil, for carbapenemase production by Gram-negative pathogens. 2019;68(2):124-131. (Current impact factor 2,112)

4. Workneh M, Yee R, Simner PJ. Phenotypic Methods for Detection of Carbapenemase Production in Carbapenem-Resistant Organisms: What Method Should Your Laboratory Choose?. Clin Microbiol Newslett. 2019;41(2):11-22. (este BDI).

5. Wu W, Feng Y, Tang G, et al. NDM metallo- β -lactamases and their bacterial producers in health care settings. Clin Microbiol Rev. 2019;32(2):e00115-18. (Current impact factor: 20,642)

6. Humphries RM. CIM City: The game continues for a better carbapenemase test. J Clin Microbiol. J Clin Microbiol. 2019;57(7). pii: e00353-19. (Current impact factor: 4,05)

7. Jousset AB, Oueslati S, Bernabeu S, et al. False-Positive Carbapenem-Hydrolyzing Confirmatory Tests Due to ACT-28, a Chromosomally Encoded AmpC with Weak Carbapenemase Activity from *Enterobacter kobei*. Antimicrob Agents Chemother. 2019;63(5). pii: e02388-18. (IF: 4,256)

8. Hughes LD, Aljawadi A, Pillai A. An overview of carbapenemase producing enterobacteriaceae (CPE) in trauma and orthopaedics. J Orthopaedics. 2019. doi.org/10.1016/j.jor.2019.06.026 (este indexat C A fara IF).

9. Pitout JD, Peirano G, Kock MM, et al. The global ascendancy of OXA-48-type carbapenemases. Clin Microbiol Rev. 2019;33(1). (IF: 17.75).

10. Jing X, Min X, Zhang X, et al. The rapid carbapenemase detection method (rCDM) for rapid and accurate detection of carbapenemase-producing Enterobacteriaceae and *Pseudomonas aeruginosa*. Front Cell Infect Microbiol. 2019;9:371. (Current impact factor: 3.518).

11. Bianco G, Boattini M, Iannaccone M, et al. Direct β -lactam inactivation method: A new low-cost assay for the rapid detection of carbapenemase-or extended-spectrum- β -lactamase-producing Enterobacterales directly from positive blood culture bottles. J Clin Microbiol. 2019. pii: JCM.01178-19. (Current impact factor: 4.959).

12. Zhong H, Wu ML, Feng WJ, Huang SF, Yang P. Accuracy and applicability of different phenotypic methods for carbapenemase detection in Enterobacteriaceae: a systematic review and meta-analysis. J Glob Antimicrob Resist. 2019. pii: S2213-7165(19)30264-4. (Current impact factor: 2.469)

13. Dabos L, Rodriguez CH, Nastro M, Dortet L, et al. LMB-1 producing *Citrobacter freundii* from Argentina, a novel player in the field of MBLs. Int J Antimicrob Agent. 2020;55(2):105857. (Current impact factor: 4.615)

14. Girlich D, Laguinde M, Dortet L, Naas T. Evaluation of the Revogene Carba C Assay for Detection and Differentiation of Carbapenemase-Producing Gram-Negative Bacteria. J Clin Microbiol. 2020;58(4). pii: e01927-19. (Current impact factor:4.959).

28. Mihai MM, Preda M, Lungu I, Gestal MC, **Popa MI**, Holban AM. Nanocoatings for Chronic Wound Repair - Modulation of Microbial Colonization and Biofilm Formation. Int J Mol Sciences. 2018;19(4):1179. ISI (FI 3,687)

22 citări, citat de (14):

1. Preda M, Holban AM, Dițu LM et al. Evaluation of the antibiotic susceptibility and virulence factors production in *Staphylococcus* spp. strains used to obtain autologous vaccine. Infectio.ro. 2018;54(2):27-31 (este indexata BDI)

2. Patil PP, Meshram JV, Bohara RA, et al. ZnO nanoparticle-embedded silk fibroin-polyvinyl alcohol composite film: a potential dressing material for infected wounds. New J Chem. 2018;42(17):14620-9. (Current impact factor: 3,201)

3. Anton-Sales I, Beekmann U, Laromaine A, et al. Opportunities of bacterial cellulose to treat epithelial tissues. Curr Drug Targets. 2019;20(8):808-822 (Current impact factor: 3,11).

4. Filomena Nazzaro, Florinda Fratianni, Antonio d'Acierno, et al. Essential Oils and Microbial Communication. In book: Essential Oils - Oils of Nature. InTech Open. 2019 (este carte).
 5. Paduraru A, Ghitulica C, Trusca R. Antimicrobial Wound Dressings as Potential Materials for Skin Tissue Regeneration. Materials (Basel). 2019;12(11). pii: E1859. (Current impact factor: 2,467)
 6. Mihai MM, Dima MB, Dima B, Holban AM. Nanomaterials for Wound Healing and Infection Control. Materials (Basel). 2019;12(13). (IF: 2,972).
 7. Sun L, Han J, Liu Z, Wei S, Su X, Zhang G. The facile fabrication of wound compatible anti-microbial nanoparticles encapsulated Collagenous Chitosan matrices for effective inhibition of poly-microbial infections and wound repairing in burn injury care: Exhaustive in vivo evaluations. J Photochem Photobiol B: Biology. 2019;111539.4 (Current Impact Factor: 4,067)
 8. Grimaudo MA, Concheiro A, Alvarez-Lorenzo C. Nanogels for regenerative medicine. J Control Release. 2019;313:148-160. (IF: 7,901).
 9. Fulaz S, Vitale S, Quinn L, Casey E. Nanoparticle–Biofilm Interactions: The Role of the EPS Matrix. Trends Microbiol. 2019;27(11):915-926. (Current impact factor: 11.974).
 10. Greta B. Antibiotic susceptibility and some persistence factors of Gram-negative bacilli isolated from trophic ulcers. Mold Med J. 2019;62(3). (este BDI).
 11. Liakos IL, Menager C, Guigo N, et al. Suberin/trans-cinnamaldehyde oil nanoparticles with antimicrobial activity and anticancer properties when loaded with paclitaxel. ACS Appl Bio Mater. 2019;2(8):3484-97. (este BDI).
 12. Fijan S, Frauwallner A, Langerholc T, et al. Efficacy of Using Probiotics with Antagonistic Activity against Pathogens of Wound Infections: An Integrative Review of Literature. BioMed Res Intl. 2019;2019:7585486. (Current impact factor:2.197).
 13. Balan G. Antibiotic susceptibility and some persistence factors of Gram-negative bacilli isolated from trophic ulcers. Moldovan Medical Journal.2019;62(3):13-17. (Este BDI).
 14. Gebreel DT, Ahmed NM, Youssef EA. The Healing Effect of a Topical Mixture of Apricot Seeds and Curcumin on Second Degree Burn Wounds in Rat. Journal of Biotechnology and Biochemistry.2019;5(6):26-33. (Este BDI).
 15. Haidar NB. Développement d'un pansement à libération contrôlée d'une protéine spécifique anti-biofilm bactérien. Application aux plaies chroniques (Doctoral dissertation, Normandie Université). 2019. (teza de dizertatie).
 16. Haidar NB, Marais S, Dé E, et al. Chronic wound healing: A specific antibiofilm protein-asymmetric release system. Mater Sci Eng C Mater Biol Appl. 2020;106:110130. (Current impact factor: 4.959)
 17. Ekram S, Ali SR, Salim A, Khan I. Role of gold-and silver-based nanoparticles in stem cells differentiation. In Metal Nanoparticles for Drug Delivery and Diagnostic Applications 2020:99-118. Elsevier. (Este carte).
 18. Marković D, Vasiljević J, Ašanin J, et al. The influence of coating with aminopropyl triethoxysilane and CuO/Cu₂O nanoparticles on antimicrobial activity of cotton fabrics under dark conditions. Journal of Applied Polymer Science. 2020. doi.org/10.1002/app.49194 (Current impact factor: 2.188)
 19. Permana AD, Mir M, Utomo E, Donnelly RF. Bacterially sensitive nanoparticle-based dissolving microneedles of doxycycline for enhanced treatment of bacterial biofilm skin infection: A proof of concept study. Int J Pharm. 2020;119220. (Current impact factor: 4.213).
 20. Zarubova J, Hasani-Sadrabadi MM, Bacakova L, Li S. Nano-in-Micro Dual Delivery Platform for Chronic Wound Healing Applications. Micromachines. 2020;11(2):158-162.(Current impact factor:2.426).
 21. Vasile BS, Birca AC, Musat MC, Holban AM. Wound Dressings Coated with Silver Nanoparticles and Essential Oils for The Management of Wound Infections. Materials (Basel). 2020;13(7). pii: E1682. (Current impact factor: 2.972).
 22. Stojkovska J, Zvicer J, Obradovic B. Preclinical functional characterization methods of nanocomposite hydrogels containing silver nanoparticles for biomedical applications. Appl Microbiol Biotechnol. 2020. doi: 10.1007/s00253-020-10521-2. (Current impact factor: 3.67).
- 29.** Tamarozzi F, Akhan O, Cretu CM, Vutova K, Akinci D, Chipeva R, Ciftci T, Constantin CM, Massimo Fabiani, Golemanov B, Janta D, Mihailescu P, Muhtarov M, Orsten S, Petrusescu M, Pezzotti P, Popa AC, Popa GL, **Popa MI**, Velev V, Siles-Lucas M, Brunetti B, Casulli C. Prevalence of abdominal cystic echinococcosis in rural Bulgaria, Romania, and Turkey: a cross-sectional, ultrasound-based, population study from the HERACLES project. Lancet Inf Dis. 2018;18(7):769-778 **C A** (FI 25,148)
- 28 citari**, citat de **(21)**:
1. Qian MB, Zhou XN. Walk together to combat echinococcosis. Lancet Inf Dis. 2018;18(9):946. (Current impact factor: 25,148)
 2. Flisser A. Eliminating cystic echinococcosis in the 21st century. Lancet Inf Dis. 2018;18(7):703-4. (Current impact factor: 25,148)
 3. Ruh E, Taylan Özkan A. Cystic Echinococcosis in Northern Cyprus: A Literature Review. Cyprus J Med Sci. 2018;3(3):193-6. (este BDI).
 4. European Food Safety Authority and European Centre for Disease Prevention and Control (EFSA AND ECDC). The European Union summary report on trends and sources of zoonoses, zoonotic agents and food-borne outbreaks in 2017. EFSA Journal, 2018;6:12: e05500. (indexat **C A** fara IF)
 5. EFSA Panel On Biological Hazards (BIOHAZ), et al. Public health risks associated with food-borne parasites. EFSA Journal, 2018;16:12: e05495. (indexat **C A** fara IF)
 6. Popov M. Wrongly interpreted icteric syndrome in outpatient practice. J Microbiol Biotechnol Rep. 2018;2.3. (Este BDI)
 7. Laivacuma S, Dekšne G, Jokelainen P, et al. Risk Factors for Human Cystic Echinococcosis in Latvia. Vector Borne Zoonotic Dis. 2019. doi: 10.1089/vbz.2018.2354 (Current impact factor: 2,171)
 8. Kaminstein D, Heller T, Tamarozzi F. Sound Around the World: Ultrasound for Tropical Diseases. Infect Dis Clin. 2019;33(1):69-195. (Este BDI)
 9. Wen H, Vuitton L, Tuxun T et al. Echinococcosis: Advances in the 21st Century. Clin Microbiol Rev. 2019;32(2). pii: e00075-18. (Current impact factor: 20,642)
 10. Tamarozzi F, Akhan O, Cretu CM, et al. Epidemiological factors associated with human cystic echinococcosis: a semi-structured questionnaire from a large population-based ultrasound cross-sectional study in eastern Europe and Turkey. Parasit Vectors. 2019;12(1):371 (Current impact factor: 3,031)
 11. Hallweaver M, McBeth C, Stolz L. et al. Ultrasound in the Limited-Resource Setting: A Systematic Qualitative Review. Curr Radiol Rep. 2019;7:21. (este BDI).
 12. Cassini R, Simonato G, Mulatti P, et al. A new approach to outbreak management for bovine Cystic Echinococcosis cases in hypo-endemic areas. Vet Parasitol Reg Stud Reports. 2019;16:100269 (este BDI).
 13. Casulli A, Siles-Lucas M, Tamarozzi F. Echinococcus granulosus sensu lato. Trends Parasitol. 2019. S1471-4922(19)30110-2. (IF: 7,929)
 14. Khan A, Ahmed H, Budke CM. Echinococcosis in Pakistan: a call for research. Lancet Inf Dis. 2019;19(6):581 (Current impact factor: 27,516).
 15. Pozio E. How globalization and climate change could affect foodborne parasites. Exp Parasitol. 2019:107807. (Current impact factor: 1,719).
 16. Khan A, Ahmed H, Simsek S. Make Headway for Echinococcosis: Take along the Ignored Cases. Iran J Parasitol. 2019;14(3):497-498. (IF: 0.735).
 17. Wang L, Gao J, Lan X, et al. Identification of combined T-cell and B-cell reactive Echinococcus granulosus 95 antigens for the potential development of a multi-epitope vaccine. AnnTransl Med. 2019;7(22):652. (Current impact factor:3.689)
 18. Tamarozzi F, Akhan O, Cretu CM. Potential risk factors associated with human cystic echinococcosis: a semi-structured questionnaire from a large population-based ultrasound cross-sectional study in Eastern Europe and Turkey. Parasit Vectors. 2019;12(1):371. (Current impact factor: 3.031)
 19. Casulli A, Siles-Lucas M, Cretu CM, et al. Achievements of the HERACLES Project on Cystic Echinococcosis. Trends Parasitol. 2020;36(1):1-4 (Current impact factor: 7,929).
 20. Mustapayeva A, Manciu T, Zholdybay Z, et al. Incidence Rates of Surgically Managed Cystic Echinococcosis in Kazakhstan, 2007-2016. Am J Trop Med Hygiene. 2020;102(1):90-5. (Current impact factor:2.315)
 21. Mirbadie SR, Zivdari M, Kalani H, et al. Molecular identification of Echinococcus granulosus sensu lato by mitochondrial COX1 and SSU-rDNA markers in dogs in the west of Iran. Gene Rep. 2020;19:100616 (indexat **C A** fara IF).
 22. Kara M, Davarci I, Dabanlioglu B. Prevalence of cystic echinococcosis in humans in Erzincan Province. Annals of Medical Research. 2020;27(1):128-32. (Este BDI).
 23. Paternoster G, Boo G, Wang C, et al. Epidemic cystic and alveolar echinococcosis in Kyrgyzstan: an analysis of national surveillance data. Lancet Glob Health. 2020;8(4):e603-e611. (Current impact factor: 15.87)

24. Tamarozzi F, Deplazes P, Casulli A. Reinventing the Wheel of Echinococcus granulosus sensu lato Transmission to Humans. Trends in Parasitology. 2020. DOI: 10.1016/j.pt.2020.02.004 . (Current impact factor: 8.02)
25. Tomasevica I, Kovačević DB, Jambrak AR et al. Comprehensive insight into the human route of food safety culture in Central and Eastern Europe. Food Control. 2020;107238. (Current impact factor: 4.248)
26. Casulli A. Recognising the substantial burden of neglected pandemics cystic and alveolar echinococcosis. Lancet Glob Health. 2020;8(4):e470-e471. (Current impact factor: 15.873)
27. Lalev MP, Simeonova JI, Stoyanov L, et al. Incidence of echinococcosis in the Plevna region of Bulgaria in the period 1998-2017. 2020. Archiv Balk Med Union 55(1):98-107 (este BDI).
28. Mihailescu PE, Istrate CM, Lazar V. Echinococcus species, neglected food borne parasites: taxonomy, life cycle and diagnosis. Biointer Res Appl Chem. 2020;10(2),5284 – 5295 (este indexata CA).

30. Georgescu SR, Mitran CI, Mitran MI, Caruntu C, Sarbu MI, Matei C, Nicolae I, Tocut SM, **Popa MI**, Tampa M. New Insights in the Pathogenesis of HPV Infection and the Associated Carcinogenic Processes: The Role of Chronic Inflammation and Oxidative Stress. J Immunol Res. 2018; doi.org/10.1155/2018/5315816 (all authors – equal) **C A** (FI 3,298)

24 citari, citat de **(16)+ (1 autocitare)**:

1. Dai L, Zhao M, Jiang W, et al. KSHV co-infection, a new co-factor for HPV-related cervical carcinogenesis?. Am J Cancer Res. 2018;8(11):2176-2184. (Current impact factor: 4.737)
2. Estevao D, Costa NR, Gil da Costa RM, Medeiros R. Hallmarks of HPV carcinogenesis: The role of E6, E7 and E5 oncoproteins in cellular malignancy. Biochim Biophys Acta Gene Regul Mech. 2019;1862(2):153-162 (este BDI).
3. Shah S, Kalal BS. Oxidative stress in cervical cancer and its response to chemoradiation. Turk J Obstet Gynecol. 2019;16:124-8. (indexat C A fara IF).
4. Erturan I, Kumbul Doguc D, et al. Evaluation of oxidative stress in patients with recalcitrant warts. J Eur Acad Dermatol Venereol. 2019. Doi: 10.1111/jdv.15746 (Current impact factor: 5.113)
5. Artaza-Irigaray C, Molina-Pineda A, Aguilar Lemarroy A, et al. E6/E7 and E6* from HPV16 and HPV18 upregulate IL-6 expression independently of p53 in keratinocytes. Frontiers in immunology. 2019;10:1676. (Current impact factor: 4.716).
6. Jelić M. Ispitivanje 8-hidroksi-2-deoksiguanozina, produkata lipidne peroksidacije i aktivnosti antioksidativnih enzima kod prekanceroznih lezija iu karcinomu grlića materice. 2019 (teza de dizertatie).
7. Neagu M, Constantin C, Bostan M, et al. Proteomic Technology “Lens” for Epithelial-Mesenchymal Transition Process Identification in Oncology. Analytic Cell Pathol. 2019;2019: 1-17 (Current impact factor: 1,788)
8. Mitran CI, Nicolae I, Mitran MI, et al. The Relationship between the Soluble Receptor for Advanced Glycation End Products and Oxidative Stress in Patients with Palmoplantar Warts. Medicina. 2019;55(10):706. (Current impact factor: IF: 1,467).
9. Hemmat N, Bannazadeh Baghi H. Association of human papillomavirus infection and inflammation in cervical cancer. Pathogens and disease. 2019;77(5):ftz048. (Current impact factor: 2,182).
10. Cioti AM, Stanescu AM, Grajdeanu IV, et al. Clinical Manifestations And Burden Of Hpv Infection–Prevention And Therapeutic Possibilities. Arch Balkan Med Union. 2019;54(4):739-744. (Este BDI).
11. Eram S, Kumar DS, Kishore P, et al. Cervical Cancer- A Review. J Med Sci Clin Res. 2019;7(12):718-722. (Este BDI).
12. Doyle C, Swain WA, Ewald PW. Inflammation, infection and depression: an evolutionary perspective. Evolutionary Human Sciences. 2019;1.doi:10.1017/ehs.2019.15 (Este BDI)
13. Aguilar-Cazares D, Chavez-Dominguez R, Carlos-Reyes A, et al. Contribution of angiogenesis to inflammation and cancer. Front Oncol. 2019;9:1399 (Current impact factor: 4.137).
14. Christobel RG, Jaganathan SS, Abirami MP, et al. A natural coumestan wedelolactone targets inflammatory cytokines to initiate apoptosis in human cervical cancer cells. Int J Pharm Sci Res. 2019; 10(12): 5657-5663. (Indexata C A)
15. 陈琳, 何迎春, 吕炎, 戴娜, 胡梅, 蔺婷, 江志超. 细胞焦亡与肿瘤的关系. 中国癌症防治杂志. 2019;10(6):488-91.
16. Ramadhanti A. Perbedaan kejadian kondiloma akuminata pada pasien hiv berdasarkan stadium klinis infeksi hiv di rsud dr. H. Abdul Moeloek Provinsi Lampung Tahun 2017-2019 (teza de doctorat).
17. Koshiyama M, Nakagawa M, Ono A. The Preventive Effect of Dietary Antioxidants Against Cervical Cancer Versus the Promotive Effect of Tobacco Smoking. Healthcare. 2019;7(4): pii: E162 (indexata C A).
18. Zhao L, Hu H, Gustafsson JA, Zhou S. Nuclear Receptors in Cancer Inflammation and Immunity. Trends Immunol. 2020;41(2):172-185 (IF: 13,00)
19. Liu Y, Li L, Ying Li, Zhao X. Research Progress on Tumor-Associated Macrophages and Inflammation in Cervical Cancer. BioMed Res Int. 2020. 6842963, doi.org/10.1155/2020/6842963 (Current impact factor: 2.197).
20. Georgescu SR, Tampa M, Mitran CI, et al. Tumour Microenvironment in Skin Carcinogenesis. Adv Exp Med Biol. 2020;1226:123-142. (IF:2.126)
21. Scheau C, Badarau IA, Mihai LG, et al. Cannabinoids in the Pathophysiology of Skin Inflammation. Molecules. 2020;25(3):E652 (IF: 3.06).
22. Pfaffenzeller MS, Franciosi MLM, Cardoso AM. Purinergic signaling and tumor microenvironment in cervical Cancer. Purinergic Signal. 2020; doi.org/10.1007/s11302-020-09693-3. (Current impact factor:3.038).
23. Liang Z, Xu C, Ji AL, et al. Effects of short-term ambient air pollution exposure on HPV infections: A five-year hospital-based study. Chemosphere. 2020;126615. (Current impact factor:5.108)
24. Tampa M, Mitran CI, Mitran MI, et al. The Role of Beta HPV Types and HPV-Associated Inflammatory Processes in Cutaneous Squamous Cell Carcinoma. J Immunol Res. 2020;2020 (Current impact factor:3.404).

31. Tampa M, Mitran MI, Mitran CI, Sarbu MI, Matei C, Nicolae I, Caruntu A, Tocut SM, **Popa MI**, Caruntu C, Georgescu SR. Mediators of Inflammation–A Potential Source of Biomarkers in Oral Squamous Cell Carcinoma. J Immunol Res. 2018;2018:1061780. **C A** (FI 3,289)

7 citari, citat de **(5) + (1 autocitare)**:

1. Neagu M, Constantin C, Bostan M, Caruntu C, et al. Proteomic Technology “Lens” for Epithelial-Mesenchymal Transition Process Identification in Oncology. Analytic Cell Pathol. 2019;2019:1-17 (Current impact factor: 1,788)
2. Mitran MI, Nicolae I, Tampa M, et al. Reactive Carbonyl Species as Potential Pro-Oxidant Factors Involved in Lichen Planus Pathogenesis. Metabolites. 2019;9(10):213. (Current impact factor IF: 3,303).
3. Thongprasom K, Phattaratatip E. Chronic Oral Mucosal Trauma and Oral Cancer: A Series of Cases. Arch Dent. 2019;1(1):14-19. (este BDI).
4. Wang Z, Zhu X, Dong P, Cai J. Long noncoding RNA LINC00958 promotes the oral squamous cell carcinoma by sponging miR-185-5p/YWHAZ. Life Sciences. 2019;242:116782. (Current impact factor: 3,448)
5. Georgescu SR, Tampa M, Mitran CI, et al. Tumour Microenvironment in Skin Carcinogenesis. Adv Exp Med Biol. 2020;1226:123-142. (IF:2.126)
6. Tampa M, Mitran CI, Mitran MI, et al. The Role of Beta HPV Types and HPV-Associated Inflammatory Processes in Cutaneous Squamous Cell Carcinoma. J Immunol Res. 2020;2020 (Current impact factor:3.404).
7. Chen F, Li XH, Liu C, et al. Circ-ABC10 accelerates the malignant progression of oral squamous cell carcinoma by absorbing miRNA-145-5p. Eur Rev Med Pharmacol Sci. 2020 Jan 1;24(2):681-90 (Current impact factor:2.721).

32. Georgescu SR, Tampa M, Mitran MI, Mitran CI, Sarbu MI, Nicolae I, Matei C, Caruntu C, Neagu M, **Popa MI**. Potential pathogenic mechanisms involved in the association between lichen planus and hepatitis C virus infection (Review). Experimental and Therapeutic Medicine. 2019;17(2):1045-51 **C A** (FI 1,41)

6 citari, citat de **(2) + (1 autocitare)**:

1. Takahashi M, Yokoyama E, Yasuhara C, et al. Metal patch test on oral lichen planus and a history of hepatitis C virus infection. J Cutan Immunol Allergy. 2019;00:1-2.(letter to the editor) (este indexata BDI).

2. Tocut SM, Mitran MI, Mitran CI, Sarbu MI, Popa GL, Georgescu SR. Photodynamic therapy as a new therapeutic approach of oral lichen planus. J Mind Med Scie. 2019;6(1):64-71 (indexat C A fara IF).
3. Neagu M, Constantin C, Bostan M, et al. Proteomic Technology "Lens" for Epithelial-Mesenchymal Transition Process Identification in Oncology. Analytic Cell Pathol. 2019;2019:1-17 (Current impact factor: 1,788)
4. Mitran CI, Nicolae I, Mitran MI, et al. The Relationship between the Soluble Receptor for Advanced Glycation End Products and Oxidative Stress in Patients with Palmoplantar Warts. Medicina. 2019;55(10):706. (Current impact factor: 1,467)
5. Houël CM. As manifestações orais do vírus da hepatite C. 2019. (Doctoral dissertation).
6. Cholewa K, Mitas K, Zaremba B, et al. Current review of connections between lichen planus and mental disorders. Journal of Education, Health and Sport. 2020;10(3):57-65. (este BDI)
33. Cristea D, Trandafir M, Bojinca VC, Ciontea AS, Andrei MM, Popa A, Lixandru BE, Militaru CM, Nascutiu AM, Predeteanu D, Ionescu R, Popescu C, Cotar AI, **Popa MI**, Spandidos DA, Codita I. Usefulness of complex bacteriological and serological analysis in patients with spondyloarthritis. Exp Therap Med. 2019;17(5):3465-76. **C A (FI 1,41)**
1 citare, citat de:
1. Cifcibasi HS, Tan B, Goztepe A, et al. Awareness Of Symptoms And Signs In Spondyloarthritis Among Family Physicians In Edirne City Center. Turkish Med Stud J. 2019;6(2):54-9. (indexată BDI)
34. Kissling E, Rose A, Emborg HD, et al., and European IVE group. Interim 2018/19 influenza vaccine effectiveness: six European studies, October 2018 to January 2019. Eurosurveill. 2019;24(8):pii=1900121. https://doi.org/10.2807/1560-7917.ES.2019.24.1900121. **CA (FI 7,127)**. (**colaborator**)
35. Cristea CV, Gheorghe I, Czobor Barbu I, Popa LI, Ispas B, Grigore GA, Bucatariu I, Popa GL, Angelescu MC, Velican A, Marutescu L, Popa M, Chifiriuc MC, **Popa MI**. Snapshot of Phylogenetic Groups, Virulence, and Resistance Markers in Escherichia coli Uropathogenic Strains Isolated from Outpatients with Urinary Tract Infections in Bucharest, Romania. BioMed Res Int. 2019;5(1):1-8 5712371: doi.org/10.1155/2019/5712371 **CA (FI 2,583)**.
3 citari, citat de (3)
1. Kot B. Antibiotic Resistance Among Uropathogenic Escherichia coli. Polish J Microbiol. 2019;68(4):403-15. (Current impact factor: 0.776)
2. Mahmoud AT, Salim MT, Ibrahim RA, et al. Multiple Drug Resistance Patterns in Various Phylogenetic Groups of Hospital-Acquired Uropathogenic E. coli Isolated from Cancer Patients. Antibiotics. 2020;9(3):108. (Current impact factor: 2.921)
3. Mohamed SB, Hassan MM, Kambal S, et al. Genome Sequence of Escherichia coli Clone O25: H4 Sequence Type 131, Isolated from a Sudanese Patient with Urinary Tract Infection. Microbiol Resour Announc. 2020;9(11): pii: e01326-19 (Este indexata CA).
36. Manolescu LSC, Boeru C, Caruntu C, Dragomirescu CC, Goldis M, Jugulete G, Marin M, Popa GL, Preda M, Radu MC, Popa MI. A Romanian experience of syphilis in pregnancy and childbirth. Midwifery. 2019;78:58-63 https://doi.org/10.1016/j.midw.2019.07.018 **CA (FI 2,048)**.
1 citare, citat de (1):
1. Dragomirescu CC, Lixandru BE, Coldea IL, et al. Antimicrobial Susceptibility Testing for Corynebacterium Species Isolated from Clinical Samples in Romania Antibiotics (Basel). 2020;9(1):31. (IF: 2.921)
37. Mitran MI, Nicolae I, Tampa M, Mitran CI, Caruntu C, Sarbu MI, Ene CD, Matei C, Georgescu SR, **Popa MI**. Reactive carbonyl species as potential pro-oxidant factors involved in lichen planus pathogenesis. Metabolites. 2019;9:213 doi:10.3390/metabo9100213 **CA (FI 3,303)**.
38. Mitran CI, Nicolae I, Tampa M, Mitran MI, Căruntu C, Sarbu MI, Ene CD, Matei C, Ionescu AC, Georgescu SR, **Popa MI**. The relationship between the soluble receptor for advanced glycation end products and oxidative stress in patients with palmoplantar warts. Medicina. 2019;55:706 doi:10.3390/medicina55100706 **CA (FI 1,467)**.
1 citare, citat de (1):
1. Tampa M, Mitran CI, Mitran MI, et al. The Role of Beta HPV Types and HPV-Associated Inflammatory Processes in Cutaneous Squamous Cell Carcinoma. J Immunol Res. 2020;2020 (Current impact factor:3.404).
39. Trifu AI, **Popa MI**, Drăgoi AM. The comorbidity of schizophrenia and alcohol: from cognitive destruction to social isolation. Lucrare prezentată la 10th ICEEPSY 2019 (International Conference on Education and Educational Psychology), Barcelona, Spania, 9-12 Octombrie 2019. Lucrarea este publicată în The European Proceedings of Social & Behavioural Sciences; https://doi.org/10.15405/epsbs.2019.11.87; ISSN: 2357-1330, de Future Academy (www.FutureAcademy.org). 2019:787-794 (publicația este indexată Clarivate Analytics)
40. Dragomirescu CC, Lixandru BE, Coldea IL, Corneli ON, Pana M, Palade AM, Cristea VC, Suciu I, Suciu G, Manolescu LSC, Popa LG, Popa. Antimicrobial Susceptibility Testing for Corynebacterium Species Isolated from Clinical Samples in Romania Antibiotics (Basel). 2020;9(1). pii: E31. doi: 10.3390/antibiotics9010031. (FI: 2.921)

Articole publicate în reviste indexate PUBMED

1. Debeleac L, **Popa MI**, Balaș A, Iancu A, Popa L, Iancu G. Studiul circulației virusului hepatitei B la pacienți investigați în Spitalul Universitar București. Bacteriol Virusol Parazitol Epidemiol. 1995;1:37-40
2. Niculescu D, Stavri H, Teodor I, **Popa M**, Stavri D, Ciomu E, Homoș M, Popescu L. Clinical usefulness of rapid serodiagnosis in pulmonary TB by ELISA with glycolipidic antigens extracted from *M. tuberculosis* and whole BCG suspension. Rom Arch Microbiol Immunol. 1995;54(4):277-84 (1)
3. Niculescu D, **Popa MI**, Stavri H, Teodor I, Stavri D, Dorobăț O, Cozma G, Homoș M, Erșcoiu S. Serodiagnosis of tuberculous meningitis by enzyme-linked immunosorbent assay (ELISA). Rom Arch Microbiol Immunol. 1996;55(3):205-14 (1)
4. **Popa MI**. Tehnici moderne moleculare, utile în identificarea microorganismelor aparținând complexului Mycobacterium tuberculosis și testarea sensibilității la antibiotice a tulpinilor izolate. Bacteriol Virusol Parazitol Epidemiol. 1996;3-4: 122
5. **Popa MI**, Niculescu D, Stavri H, Stavri D, Teodor I, Bogdan M, Ciomu E, Marica C, Macri A. Utilitatea evidențierii prezenței anticorpilor anti-mycobacterieni. Studiul comparativ a două tehnici diferite. Bacteriol Virusol Parazitol Epidemiol. 1997;3:179-81
6. Brănuș-Gheorghiu M, Răileanu M, Ciomu E, Niculescu D, **Popa M**, Stavri H, Stavri D. Application of ELISA with antigenic glycolipids in early diagnosis of pulmonary tuberculosis. Rom Arch Microbiol Immunol. 1997;56(1-2):55-61
7. **Popa MI**, Goguet Y, Teodor I, Popa L, Stefan M, Bănică D, Gicquel B. Genomic profile of Romanian *M. tuberculosis* strains appreciated by spoligotyping. Rom Arch Microbiol Immunol. 1997;56(1-2):63-75 (3)
8. Iacob S, **Popa MI**, Bănică D. Importanța markerilor imunologici în diagnosticul infecțiilor SNC produse de mycobacterii. Bacteriol Virusol Parazitol Epidemiol. 1997;4:257-64
9. **Popa MI**, Ștefan M. Metodologii actuale și de perspectivă în diagnosticul tuberculozei. Bacteriol Virusol Parazitol Epidemiol. 1997;4:265-68
10. **Popa MI**, Stavri D, Teodor I, Niculescu D, Stavri H. Teste minimale de identificare a tulpinilor mycobacteriene implicate patogenice. Bacteriol Virusol Parazitol Epidemiol. 1998;43(1-2):95-96
11. Pițigoi D, **Popa MI**, Streinu-Cercel A. Procesul epidemiologic al infecției cu virusul West Nile. Bacteriol Virusol Parazitol Epidemiol. 1998;4:281-88
12. **Popa MI**, Pițigoi D, Ciufecu C, Popa LG. Situația bolii diareice acute în România: 1993-1998. Bacteriol Virusol Parazitol Epidemiol. 1998;4: 241-45
13. Nicolaiciuc D, Popa MI, Popa L. Malaria in the whole world and in Romania. Roum Arch Microbiol Immunol. 1999;58(3-4):289-96 (2)

14. **Popa MI**, Pițigoi D, Nicolaiciuc D, Gresie D, Pistol A, Popa LG. Date cu privire la evoluția malariei în România în perioada 1980-1998. *Bacteriol Virusol Parazitol Epidemiol*. 1999;3-4:213-217
15. Popa LG, Preoteșcu L, **Popa MI**, Rădulescu S. Hidatidoză multiviscerală complicată; particularități de diagnostic și tratament. *Bacteriol Virusol Parazitol Epidemiol*. 1999;3-4:235-238
16. Stavri H, Brănuș M, Moldovan O, Răileanu M, **Popa MI**, Popa L, Ene L. Rapid immunochromatographic serum assay of nontuberculous mycobacterial infections. *Rom Arch Microbiol Immunol*. 2005;64(1-4):42-49 (1)
17. Popa LG, **Popa MI**, Mihai I. Case-control study to evaluate the link between immunosuppression and *Candida* spp. infection. *Rom Arch Microbiol Immunol*. 2005;64(1-4):72-76 (1)
18. **Popa MI**, Stavri D, Stavri H, Popa LG, Mihai I. Establishing of a minimal set of tests (minimal standards) to identify species included in the genus *Mycobacterium*. *Rom Arch Microbiol Immunol*. 2006;65(1-2):41-45
19. Oprișan G, Coste H, Lupulescu E, Oprișoreanu AM, Szmal C, Onita I, Popovici N, Ionescu IE, Bicheru S, Enache N, Ceianu C, Czobor F, Olaru E, Alexandrescu V, Radu DL, Onu A, **Popa MI**. Molecular analysis of the first Avian Influenza H5N1 isolates from fowl in Romania. *Rom Arch Microbiol Immunol*. 2006;65(3-4):79-82 (6)
20. Băicuș A, Persu A, **Popa MI**, Băicuș C. Immunity status against Coxsackie viruses B in 25 patients with acute myocarditis. *Rom Arch Microbiol Immunol*. 2006;65(3-4):79-86
21. Stavri H, Ene L, Popa GL, Duiculescu D, Murgoci G, Marica C, Ulea I, Gabriela Cus G, **Popa MI**. Comparison of Tuberculin Skin Test with a Whole-Blood Interferon Gamma Assay and ELISA, in HIV positive children and adolescents with TB. *Rom Archives Microbiol Immunol*. 2009;68(1):14-19 (11)
22. **Popa MI**, Popa GL, Mihai A, Ocneanu M, Diaconu A. HIV and AIDS, among knowledge, responsibility and ignorance; a study on medical students at the end of their first university year. *J Med Life*. 2009;3:308-12
23. Preoteșcu L, Popa GL, Motoi M, Streinu-Cercel A, **Popa MI**. *Aspergillus fumigatus* meningitis in immunosuppressed patients; diagnosis, management, prevention and control. *Rom Arch Microbiol Immunol*. 2009;68(3):95-99 (1)
24. Ulea I, Murgoci G, **Popa MI**, Popa L, Stavri H. Comparative study of RT23 and IC-65 tuberculin tests tested on children with tuberculosis. *Rom Arch Microbiol Immunol*. 2010;69(2):75-78 (1) și (1)
25. Stavri H, Murgoci Gh, Ulea I, Popa LG, **Popa MI**. Prospective comparison of two brands of tuberculin skin tests and QuantiFERON –TB Gold in-tube assay performances for tuberculosis infection in hospitalized children. *Maedica*. 2010;5(4):271-276 (3) și (1)
26. Zaharia DC, Popa MG, Steriade AT, Muntean AA, Balint O, Micuț R, Popa VT, Popa MI, Bogdan MA. Microcalorimetry--a new method for bacterial characterisation. *Pneumologia (Bucharest, Romania)*. 2013;62(4):232-5. (1)
27. Dragomirescu CC, Coldea IL, Ilie A, Stănescu A, Ungureanu V, **Popa MI**. Seroprevalence study of anti diphtheria antibodies in two age-groups Romanian adults. *Rom Arch Microbiol Immunol*. 2014;73(1-2):18-24
28. Neguț AC, Săndulescu O, Popa M, Streinu-Cercel A, Alavidze Z, Berciu I, Bleotu C, **Popa MI**, Chifiriuc MC, Streinu-Cercel A. Experimental approach for bacteriophage susceptibility testing of planktonic and sessile bacterial populations – Study protocol. *GERMS*. 2014;4(4):92-96 (2) și (1)
29. Cristea CV, Oprea M, Neacșu G, Gîlcă R, **Popa MI**, Usein CR. Mechanisms of resistance to ciprofloxacin and genetic diversity of *Escherichia coli* strains originating from urine cultures performed for Romanian adults. *Rom Arch Microbiol Immunol*. 2015;74(3-4):73-8
30. Moisoiu A, Mitran CI, Mitran MI, Huhu MR, Ioghen OC, Gheorghe SA, Tampa M, Georgescu SR, **Popa MI**. Resistance pattern of multi-drug resistant strains of *Mycobacterium tuberculosis* and characteristics of patients with multi-drug resistant tuberculosis. *Rom Arch Microbiol Immunol*. 2016;75(1-2):25-31
31. Manolescu LSC, Corina MR, Vasileoiu R, Goldis M, Dragodan AD, Popa GL, **Popa MI**. Congenital syphilis continues to be a threat. *Rom Archives Microbiol Immunol*. 2017;76(1):50-55
32. Băicuș A, Persu A, Popa GL, **Popa MI**. Echovirus serotypes isolated in an aseptic meningitis outbreak in Romania (2007). *Rom Archives Microbiol Immunol*. 2017;76(1):56-60
33. Mitran M, Mitran C, Tampa M, Parvan AM, Sarbu I, Matei C, Trifu R, **Popa MI**, Georgescu SR. Fish tank granuloma - a challenging diagnosis. *Rom Archives Microbiol Immunol*. 2017;76(2):102-107

Numărul de citări al fiecărui articol (PUBMED)

2. Niculescu D, Stavri H, Teodor I, Popa M, Stavri D, Ciomu E, Homoș M, Popescu L. Clinical usefulness of rapid serodiagnosis in pulmonary TB by ELISA with glycolipid antigens extracted from *M. tuberculosis* and whole BCG suspension. *Rom Arch Microbiol Immunol*. 1995;54(4):277-84
6 citări, citat de: 1 (+1 autocitare)
1. Stavri H, Moldovan O, Mihaltan F, et al. Rapid dot sputum and serum assay in pulmonary tuberculosis. *J Microbiol Methods*. 2003;52(3):285-96
(Current impact factor: 2,026)
2. Stavri H, Ene L, Popa GL, et al. Comparison of tuberculin skin test with a whole-blood interferon gamma assay and ELISA, in HIV-positive children and adolescents with TB. *Rom Arch Microbiol Immunol*. 2009;68(1):14-9
(Nu are factor de impact. Este indexată BDI.)
3. Stavri H, Brănuș M, Gheorghiu M, Moldovan O, et al. Rapid immunochromatographic serum assay of nontuberculous mycobacterial infections. *Rom Arch Microbiol Immunol*. 2005;64(1-4):42-9 (Nu are factor de impact. Este indexată BDI.)
4. Stavri H, Ulea I, Radu DL, et al. Serodiagnosis of environmental mycobacterial infections. *J Microbiol Methods*. 2011;86(3):283-90 (Current impact factor: 2,026)
5. Ene L, Stavri H, Nicolaescu O, et al. The clinical significance of the tests for diagnosis of tuberculous infection for the diagnosis of tuberculosis in HIV-infected children and adolescents. *Ro J Infect Dis*. 2009;12(1):20-31.
(Nu are factor de impact. Este indexată BDI.)
6. Murgoci G, Biolan T, Nica M, Duță N, Popa M, Popa GL, Duiculescu D. Semnificația clinică a testelor de diagnostic al infecției tuberculoase în diagnosticul tuberculozei la copii și adolescenții cu infecție HIV-1. *RJID* 2009;12(1):20-31.
3. Niculescu D, Popa M, Stavri H, Teodor I, Stavri D, Dorobăț O, Cozma G, Homoș M, Erșcoiu S. Serodiagnosis of tuberculous meningitis by enzyme-linked immunosorbent assay (ELISA). *Rom Arch Microbiol Immunol*. 1996;55(3):205-14.
2 citări, citat de: (1)
1. Hongxi G, Hong L, Ruzhen G, et al. Detection of tuberculous glycolipid antibody for tuberculosis serological diagnosis by enzyme-linked immunosorbent assay. *J Chin Clin Med*. 2003;4(2):9-10 (SRJ: 0,103)
2. Haworth CS, Banks J, Capstick T, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). *Thorax*. 2017;72(Suppl 2):ii1-64. (Current impact factor: 8,272).
7. Popa MI, Goguet Y, Teodor I, Popa L, Stefan M, Bănică D, Gicquel B. Genomic profile of Romanian *M. tuberculosis* strains appreciated by spoligotyping. *Rom Arch Microbiol Immunol*. 1997;56(1-2):63-75
4 citări, citat de: 3:
1. Sola C, Filliol I, Gutierrez MC, et al. Spoligotype database of *Mycobacterium tuberculosis*: biogeographic distribution of shared types and epidemiologic and phylogenetic perspectives. *Emerg Infect Dis*. 2001;7(3):390-396 (Current impact factor: 8,222)
2. Moisoiu A, Grigoriu LA, Popa MI. Infections caused by non-tuberculous mycobacteria. *Infectio.ro*. 2014;39(3):24-28 (Nu are factor de impact. Este indexată BDI.)
3. Sola C, Filliol I, Legrand E, Rastogi N. Recent developments of spoligotyping as applied to the study of epidemiology, biodiversity and molecular phylogeny of the *Mycobacterium tuberculosis* complex. *Pathol Biol*. 2000;48(10):921-32 (Current impact factor: 1,802)

4. Brudey K, Driscoll JR, Rigouts L, et al. Mycobacterium tuberculosis complex genetic diversity: mining the fourth international spoligotyping database (SpolDB4) for classification, population genetics and epidemiology. BMC Microbiol. 2006;6:23 (Current impact factor: 2,644)
13. Nicolaiciuc D, Popa MI, Popa L. Malaria in the whole world and in Romania. Rom Arch Microbiol Immunol. 1999;58(3-4):289-96
- 4 citări, citat de 2:
 1. Gratz NG. The vector-borne human infections of Europe : their distribution and burden on public health. WHO Europe. 2004 (Volum al Organizației Mondiale a Sănătății)
 2. Neghina R, Neghina AM, Giurgiu LD, et al. Import of malaria in a Romanian Western County. Travel Med Infect Dis. 2008;6(4):215-8 (Current impact factor: 3,055)
 3. Angbo O, Kouassi DP, Coulibaly A, Dagnan S. Connaissances, attitudes et pratiques des menages en matiere de prevention du paludisme: cas d'un quartier précaire d'Abidjan, Côte d'Ivoire. Cah Santé Publique. 2008;1-9
 4. Ivanescu L, Bodale I, Florescu SA, et al. Climate Change Is Increasing the Risk of the Reemergence of Malaria in Romania. BioMed Res Int. 2016; ID 8560519:1-7 (Current impact factor: 2,476)
16. Stavri H, Brănuș M, Moldovan O, Răileanu M, Popa MI, Popa L, Ene L. Rapid immunochromatographic serum assay of nontuberculous mycobacterial infections. Rom Arch Microbiol Immunol. 2005;64(1-4):42-49
- 4 citări, citat de (1):
 1. Stavri H, Ulea I, Radu DL, et al. Serodiagnosis of environmental mycobacterial infections. J Microbiol Meth. 2011;86(3):283-290 (Current impact factor: 2,026)
 2. Leshchenko OY, Suturina LV, Popova NV. Features of diagnosis of urogenital tuberculosis in patients with infertility. Bulletin of ESCC SB RAMS. 2012;2(84):141-447. (Nu are factor de impact. Este indexată VINITI, RISC)
 3. Ulea I, Stavri H. Thin layer chromatography characterization of ELISA specific glycolipids antigens immunomagnetically purified from environmental mycobacteria. Rom Arch Microbiol Immunol. 2013;72(2):105-20 (Nu are factor de impact. Este indexată BDI)
 4. Серегина ВА, Будрицкий АМ. Современные возможности диагностики туберкулеза легких. Вестник Витебского государственного медицинского университета. 2016;15(4).
17. Popa LG, Popa MI, Mihai I. Case-control study to evaluate the link between immunosuppression and Candida spp. infection. Rom Arch Microbiol Immunol. 2005;64(1-4):72-76
- 5 citări, citat de 1:
 1. Domínguez-Meléndez V, Silvestre-Santana O, Moreno-Fierros L., et al. Sodium caseinate induces mouse granulopoiesis. Inflamm Res. 2012;61(4):367-73 (Current impact factor: 2,659)
 2. Wei G, He D, Song D, et al. Fungal inflammation of rat peritoneal exudate supernatant of anti-Candida albicans. Guiding J Tradit Chin Med Pharm. 2010;16(9):94-96 (Nu are factor de impact.)
 3. Wei G, He D, Song D, et al. The antimicrobial effect of peritoneal exudates in rat model infected by Candida albicans. Guangxi Med J. 2010;32(11):1317-20 (Nu are factor de impact.)
 4. 丰桂宁, 宋大彦, 何德明, 李艳 The supernatant of rat peritoneal inflammation exudate fungal antifungal action research. Chin J Exp Tradit Med Form. 2011 (<http://www.cqvip.com/qk/98409x/201110/37909796.html>)
 5. Ledesma-Martinez E, Domínguez-Meléndez V, Aguiñiga-Sánchez I, Santiago-Orsorio E. Caseins as Regulators of Hematopoiesis. In Milk Proteins-Biological Functions in Mammary Gland and the Neonate. 2020. IntechOpen.
18. Popa MI, Stavri D, Stavri H, Popa LG, Mihai I. Establishing of a minimal set of tests (minimal standards) to identify species included in the genus Mycobacterium. Rom Arch Microbiol Immunol. 2006;65(1-2):41-45
- 3 citări, citat de:
 1. Mitran MI, Gheorghe AS, Tănase AG, Mitran CI. Difficulties in diagnosis and treatment of pulmonary tuberculosis in the elderly. Infectio.ro. 2014;39(3):20-23 (Nu are factor de impact. Este indexată BDI)
 2. Moisoiu A, Grigoriu LA, Popa MI. Infections caused by non-tuberculous mycobacteria. Infectio.ro. 2014;39(3):24-28 (Nu are factor de impact. Indexată BDI).
 3. Tesfaye A. Evaluation of Diagnostic Algorithms, Drug Resistance, Molecular Typing, and Geospatial Clustering of Tuberculosis in Addis Ababa, Ethiopia (Doctoral dissertation, Addis Ababa University).
19. Oprișan G, Coste H, Lupulescu E, Oprișoreanu AM, Szmal C, Onita I, Popovici N, Ionescu IE, Bicheru S, Enache N, Ceianu C, Czobor F, Olaru E, Alexandrescu V, Radu DL, Onu A, **Popa MI**. Molecular analysis of the first Avian Influenza H5N1 isolates from fowl in Romania. Rom Arch Microbiol Immunol. 2006;65(3-4):79-82
- 9 citări, citat de (6):
 1. Alkhamis MA, Moore BR, Perez AM. Phylodynamics of H5N1 highly pathogenic avian influenza in Europe, 2005–2010: Potential for molecular surveillance of new outbreaks. Viruses. 2015;7(6):3310-28 (Current impact factor: 3,465)
 2. Coman A, Maftei DN, Krueger WS, et al. A prospective study of romanian agriculture workers for zoonotic influenza infections. PLoS One. 2014;9(5):e98248 (Current impact factor: 2,806)
 3. Coman A, Maftei DN, Chereches RM, et al. Avian influenza surveillance in the danube delta using sentinel geese and ducks. Influenza Res Treat. 2014;2014:965749 (Nu are factor de impact. Este indexată BDI)
 4. Alkhamis, Mohammad. University of California, Epidemiological Assessment of Avian Influenza Surveillance in Europe, ProQuest Dissertations Publishing, 2014 (nu are factor de impact, este teză de doctorat).
 5. Coman A, Maftei DN, Krueger WS, et al. Serological evidence for avian H9N2 influenza virus infections among Romanian agriculture workers. J Infect Public Health. 2013;6(6):438-47 (Current impact factor: 1,439)
 6. Alkhamis M, Perez A, Batey N, et al. Modeling the association of space, time, and host species with variation of the HA, NA, and NS genes of H5N1 highly pathogenic avian influenza viruses isolated from birds in Romania in 2005-2007. Avian Dis. 2013;57(3):612-21 (Current impact factor: 1,109)
 7. Mihai ME, Tecu C, Ivanciuc AE, et al. Survival of H5N1 influenza virus in water and its inactivation by chemical methods. Rom Arch Microbiol Immunol. 2011;70(2):78-84 (Nu are factor de impact. Este indexată BDI)
 8. Jadhao SJ, Nguyen DC, Uyeki TM, et al. Genetic analysis of avian influenza A viruses isolated from domestic waterfowl in live-bird markets of Hanoi, Vietnam, preceding fatal H5N1 human infections in 2004. Arch Virol. 2009;154(8):1249-61 (Current impact factor: 2,058)
 9. Tsunekuni R1, Yaguchi Y2, Kashima Y2, et al. Spatial transmission of H5N6 highly pathogenic avian influenza viruses among wild birds in Ibaraki Prefecture, Japan, 2016-2017. Arch Virol. 2018;163(5):1195-1207. (Current impact factor: 2,058)

21. Stavri H, Ene L, Popa GL, Duiculescu D, Murgoci G, Marica C, Ulea I, Gabriela Cus G, Popa MI. Comparison of Tuberculin Skin Test with a Whole-Blood Interferon Gamma Assay and ELISA, in HIV positive children and adolescents with TB. *Rom Archives Microbiol Immunol.* 2009;68(1):14-19
18 citări, citat de (11):
 1. Mandalakas AM, Van Wyk S, Kirchner HL, et al. Detecting tuberculosis infection in HIV-infected children: A study of diagnostic accuracy, confounding and interaction. *Pediatr Infect Dis J.* 2013;32(3):e111-e118. (Current impact factor: 2,486)
 2. Amanatidou V, Syridou G, Mavrikou M, Tsoia MN. Latent tuberculosis infection in children: Diagnostic approaches. *Eur J Clin Microbiol Infect Dis.* 2012;31(7):1285-94 (Current impact factor: 2,727)
 3. Connell TG, Zar HJ, Nicol MP. Advances in the diagnosis of pulmonary tuberculosis in HIV-infected and HIV uninfected children. *J Infect Dis.* 2011;204(Suppl.4):S1151-58 (Current impact factor: 6,273)
 4. Mandalakas AM, Detjen AK, Hesselning AC, et al. Interferon-gamma release assays and childhood tuberculosis: Systematic review and meta-analysis. *Int J Tuberc Lung Dis.* 2011;15(8):1018-32 (Current impact factor: 2,468)
 5. Ling DI, Zwerling AA, Steingart KR, Pai M. Immune-based diagnostics for TB in children: What is the evidence? *Paediatr Res Rev.* 2011;12(1):9-15 (Current impact factor: 2,214)
 6. Al-Zamel FA. Detection and diagnosis of Mycobacterium tuberculosis. *Expert Rev Anti Infect Ther.* 2009;7(9):1099-108 (Current impact factor: 3,139)
 7. Hoffmann M, Ravn P. The use of interferon-gamma release assays in HIV-positive individuals. *Eur J Clin Microbiol Infect Dis.* 2010;4(1):23-29 (Current impact factor: 2,727)
 8. Stavri HR, Murgoci G, Ulea I, et al. Prospective Comparison of Two Brands of Tuberculin Skin Tests and Quantiferon-TB Gold in-tube Assay Performances for Tuberculosis Infection in Hospitalized Children. *Maedica.* 2010;5(4):271-76 (Nu are factor de impact. Este indexată BDI.)
 9. Al-Zamel F. Diagnosis of Mycobacterium tuberculosis. INTECH Open Access Publisher. 2012 (Nu are factor de impact. Este carte.)
 10. Cruz AT, Mandalakas AM. New advances in the diagnosis and treatment of pediatric tuberculosis. *Clin Investig.* 2013;3(1):69-82 (Nu are factor de impact. Este indexată BDI)
 11. 孙琳, et al. 儿童结核病的诊断. 标记免疫分析与临床. 2011;18(3):201-6.
 12. 蓝陆地. 两种双抗原夹心法检测抗人类免疫缺陷病毒抗体的方法比较. *中国基层医药.* 2012;19(002):185-87
 13. Hormi M, Guérin-El Khourouj V, Pommelet V, et al. Performance of the Quantiferon-tb Gold Assay Among Hiv-infected Children with Active Tuberculosis in France. *Pediatr Infect Dis J.* 2018;37(4):339-344. (Current impact factor: 2,486)
 14. Overton K, Varma R, Post JJ. Comparison of Interferon-γ Release Assays and the Tuberculin Skin Test for Diagnosis of Tuberculosis in Human Immunodeficiency Virus: A Systematic Review. *Tuberc Respir Dis.* 2018;81(1):59-72 (Indexata ISI fara factor de impact).
 15. Meier NR, Volken T, Geiger M, et al. Risk Factors for Indeterminate Interferon-Gamma Release Assay for the Diagnosis of Tuberculosis in Children—A Systematic Review and Meta-Analysis. *Froniers in Pediatrics.* 2019;7:208. (Current impact factor: 2.335).
 16. Starshinova A, Dovgalyuk F, Yablonskiy P. Immunodiagnosics of tuberculosis: 10-year experience of using immunological tests in Russia. *Главная.* 2019;97(5):58-65. (este indexata BDI).
 17. Старшинова АА, Довгальук ИФ, Яблонский П.К. Иммунодиагностика туберкулеза: десятилетний опыт применения иммунологических тестов в России. *Туберкулез и болезни легких.* 2019;97(5):58-65.
 18. Almeida Santos J, Duarte R, Nunes C. Tuberculin skin test and predictive host factors for false negative results in patients with pulmonary and extrapulmonary tuberculosis. *Clin Respir J.* 2020. doi: 10.1111/crj.13166 (Current impact factor: 1.75)
22. Popa MI, Popa GL, Mihai A, Ocneanu M, Diaconu A. HIV and AIDS, among knowledge, responsibility and ignorance; a study on medical students at the end of their first university year. *J Med Life.* 2009;3:308-12
4 citări, citat de:
 1. Ayankogbe OO, Odusote K, Omoegun MO, et al. Determinants of young people's sexual behaviour concerning HIV and AIDS in the practice population of a university health centre in Lagos, Nigeria. *Afr J Prim Health Care Family Med.* 2011;3(1):219. (SRJ: 0,18)
 2. Cyburski M, Pawłowska M, Krzyzak M, et al. Knowledge about HIV and attitudes towards people with HIV/AIDS among students of Public Health, Medical University of Białystok. *Probl. Hig. Epidemiol.* 2012;93(3):618-622 (Nu are factor de impact)
 3. de Souza Praca N, de Freitas P, Kimura AF. Knowledge about HIV/AIDS on women's health: a descriptive study with undergraduates. *Online J Nurs.* 2013;12(2):359-376 (Nu are factor de impact)
 4. Zivanovic S, Supic V, Hadzivukovic N, Kulic V. Knowledge and attitudes of high school students about sexually transmitted diseases. *Sestrinska Rec.* 2017;21(74):14-7
23. Preoteșcu L, Popa GL, Motoi M, Streinu-Cercel A, Popa MI. Aspergillus fumigatus meningitis in immunosuppressed patients; diagnosis, management, prevention and control. *Rom Arch Microbiol Immunol.* 2009;68(3):95-99
1 citare, citat de 1:
 1. Upadhyay SK, Creech CC, Bowdy KL, et al. Synthesis and antifungal activity of functionalized 2,3-spirostane isomers. *Bioorg Med Chem Lett.* 2011;21(10):2826-31 (Current impact factor: 2,454)
24. Ulea I, Murgoci G, Popa MI, Popa L, Stavri H. Comparative study of RT23 and IC-65 tuberculins tested on children with tuberculosis. *Rom Arch Microbiol Immunol.* 2010;69(2):75-78
3 citări, citat de 1:
 1. Yang H, Kruh-Garcia NA, Dobos KM. Purified protein derivatives of tuberculin - past, present, and future. *FEMS Immunol Med Microbiol.* 2012;66(3):273-80 (Current impact factor: 3,078)
 2. Stavri H, Bucurenci N, Ulea I, et al. Use of recombinant purified protein derivative (PPD) antigens as specific skin test for tuberculosis. *Indian J Med Res.* 2012;136 (5):799-807 (Current impact factor: 1,396)
 3. Stavri HR, Murgoci G, Ulea I, et al. Prospective Comparison of Two Brands of Tuberculin Skin Tests and Quantiferon-TB Gold in-tube Assay Performances for Tuberculosis Infection in Hospitalized Children. *Maedica.* 2010;5(4):271-76 (Nu are factor de impact. Este indexată BDI.)
25. Stavri H, Murgoci Gh, Ulea I, Popa LG, Popa MI. Prospective comparison of two brands of tuberculin skin tests and Quantiferon –TB Gold in-tube assay performances for tuberculosis infection in hospitalized children. *Maedica.* 2010;5(4):271-276
7 citări, citat de (3):
 1. Sollai S, Galli L, de Martino M, Chiappini E. Systematic review and meta-analysis on the utility of Interferon-gamma release assays for the diagnosis of Mycobacterium tuberculosis infection in children: a 2013 update. *BMC Infect Dis.* 2014;14(Suppl.1):S6 (Current impact factor: 2,768)
 2. Prasad TS, Verma R, Kumar S, et al. Proteomic analysis of purified protein derivative of Mycobacterium tuberculosis. *Clin Proteomics.* 2013;10(1):8 (Current impact factor: 3,274)
 3. Stavri H, Bucurenci N, Ulea I, et al. Use of recombinant purified protein derivative (PPD) antigens as specific skin test for tuberculosis. *Indian J Med Res.* 2012;136(5):799-807 (Current impact factor: 1,396)
 4. Ulea I, Murgoci G, Popa MI, et al. Comparative study of RT23 and IC-65 tuberculins tested on children with tuberculosis. *Rom Arch Microbiol Immunol.* 2010;69(2):75-8 (Nu are factor de impact. Este indexată BDI.)

5. 汪乾坤 et al. 猕猴结核 IFN- γ 体外释放检测法的建立与初步应用. 中国兽医学报. 2015;35(9):1488-94.
 6. Meier NR, Volken T, Geiger M, et al. Risk Factors for Indeterminate Interferon-Gamma Release Assay for the Diagnosis of Tuberculosis in Children—A Systematic Review and Meta-Analysis. *Frontiers in Pediatrics*. 2019;7:208. (Current impact factor:2.335).
 7. Parfeni O, Cristea A. Date privind complianța la tratament a pacienților din județul Harghita. *Infectio. ro*. 2017(50):30-3.
- 26.** Zaharia DC, Popa MG, Steriade AT, Muntean AA, Balint O, Micuț R, Popa VT, Popa MI, Bogdan MA. Microcalorimetry--a new method for bacterial characterisation. *Pneumologia (Bucharest, Romania)*. 2013;62(4):232-5.
1 citare, citat de (1):
Flores D, Panic G, Braissant O, Keiser J. A novel isothermal microcalorimetry tool to assess drug effects on *Ancylostoma ceylanicum* and *Necator americanus*. *Appl Microbiol and Biotechnol*. 2016 Jan 1;100(2):837-46. (Current impact factor:3.67)
- 27.** Dragomirescu CC, Coldea IL, Ilie A, Stanescu A, Ungureanu V, **Popa MI**. Seroprevalence study of anti diphtheria antibodies in two age-groups Romanian adults. *Rom Arch Microbiol Immunol*. 2014;73(1-2):18-24
5 citări, citat de:
1. Gheorghe AS, Preda M, Popa GL, Popa MI. A potentially fatal disease preventable by vaccination produces a victim in Spain and rises a worldwide alert of the existing risk. *Infectio.ro*. 2015;43(3):5-9 (Nu are factor de impact. Este indexată BDI.)
2. Asociación Española de Pediatría. Manual de vacunas en línea de la aep. 2014. (Nu are factor de impact. Este carte/volum.)
<http://vacunasae.org/documentos/manual/manual-de-vacunas>
3. Popa GL, Gheorghe AS, Preda M, Popa MI. The recent experience of Belgium on diphtheria and the need to adopt prevention measures, in order to avoid future fatal cases. *Infectio. ro*. 2016.45(1):25. (Este indexată BDI).
4. Konshina OS, Eropkin MY, Nikonorov IY, Pozdnyakova MG. Role of biobanks in the study of population immunity ЖУРНАЛ ИНФЕКТОЛОГИИ Том 10, № 2, 2018 DOI: 10.22625/2072-6732-2018-10-2-39-47 (este indexată BDI).
5. Cakar SE, Ceran N, Karagoz G, Tulgar Y, Demir ZA, Kadanali A. Is diphtheria booster vaccination still necessary in Turkey? *Medit J Inf Microbes Antimicrob*. 2018 Jan 1;7. – POATE CĂ NU ESTE INDEXATĂ NICI MĂCAR BDI
- 28.** Neguț AC, Săndulescu O, Popa M, Streinu-Cercel A, Alavidze Z, Berciu I, Bleotu C, **Popa MI**, Chifiriuc MC, Streinu-Cercel A. Experimental approach for bacteriophage susceptibility testing of planktonic and sessile bacterial populations – Study protocol. *GERMS*. 2014;4(4):92-96
6 citări, citat de: (2) (+2 autocitări)
1. Neguț AC, Streinu-Cercel A, Popa MI. Bacteriophagii, trecut și prezent, o alternativă viabilă în terapia antimicrobiană?/Bacteriophages, past and present, a viable alternative in antimicrobial therapy?. *Infectio. ro*. 2015;44:13.
2. Neguț AC, Chifiriuc MC, Săndulescu O, et al. Bacteriophage-driven inhibition of biofilm formation in *Staphylococcus* strains from patients attending a Romanian reference center for infectious diseases. *FEMS Microbiology Letters*. 2016;363(18). (Current Impact Factor: 1,765)
3. Neguț AC, Streinu-Cercel A, Săndulescu O, et al. Bacteriophages—novel biotechnology tools available in clinical practice in Romania.2017. *Romanian Biotechnological Letters*. 2017;22(2):12492. (Current Impact Factor: 0,59)
4. Tkhalishvili T, Di Luca M, Abbandonato G, Maiolo EM, Klatt AB, Reuter M, Möncke-Buchner E, Trampuz A. Real-time assessment of bacteriophage T3-derived antimicrobial activity against planktonic and biofilm-embedded *Escherichia coli* by isothermal microcalorimetry. *Res Microbiol*. 2018;169(9):515-521. (Current impact factor: 2,372)
5. Kim G, Ahn D, Kang M, et al. Rapid and label-free identification of individual bacterial pathogens exploiting three-dimensional quantitative phase imaging and deep learning. *BioRxiv*. 2019:596486 (este BDI).
6. Cepko LC, Garling EE, Dinsdale MJ, et al. Myoviridae phage PDX kills enteroaggregative *Escherichia coli* without human microbiome dysbiosis. *J Med Microbiol*. 2020;69(2):309-23. (Current impact factor: 1.926)
- Broșură internațională**
- Granstrom M, Molnar Z, Navarro-Alonso JA, **Popa MI**, et al. ECDC GUIDANCE: Scientific panel on childhood immunisation schedule: Diphtheria, tetanus, pertussis (DTP) vaccination, Stockholm. November 2009
6 citări, citat de (1):
1. Nolte S. Impfungen – zu viel des Guten?. *Zeitschrift für Komplementärmedizin*. 2013;2:30-33 (este o revista BDI)
2. Kieninger DM, Knuf M. The missing dose. *Kinder- und Jugendmedizin*. 2014;14(1):7-13 (este o revista BDI)
3. Jäger-Becker D. Grundimmunisierung und Auffrischimpfungen bleiben wichtig. *Kinder- und Jugendmedizin*. 2018;18(1):61 (este o revista BDI)
4. Gabutti G, Trucchi C, Conversano M, Zivelonghi G, Zoppi G. Booster vaccination: the role of reduced antigen content vaccines as a preschool booster. *BioMed Res Int*. 2014;2014. (Current impact factor: 2,583)
5. von Segebaden K. Kikhosta en risk för spädbarn. Kikhosta en risk för spädbarn. *Läkartidningen* 2013;110:CFRI (este indexată BDI).
6. Pertet AM, Kaseje D, Odawa CO, Ochieng J, Kirika L, Wanjala C, Jaoko M, Otieno W, Odindo D. Completion, timeliness, and under-vaccination of childhood vaccinations in a nomadic pastoralist community of Kenya. *Int J Contemp Ped*. 2018;5(4):1162-7. (este indexată BDI)
- Capitole carte**
1. Possenti V, De Mei B, Scardetta P, Kurchatova A, Manfred Green M, Harald Drager K, Haukeland J, Eva Benelli E, d'Onofrio A, Baka A, Saadatian M, Moore VM, Brattekas K, Beresniak A, Popa MI, Greco D, Perra A, 2018, The ASSET Research Project as a Tool for Increased Levels of Preparedness and Response to Public Health Emergencies (chapter 9), pag. 65-78, in *Responsible Research and Innovation Actions in Science Education, Gender and Ethics, Cases and Experiences*, Ferri F, Dwyer F, Raicevich S, Grifoni P et al (editors), Ed. Springer, Cham, ISBN 978-3-319-73206-0; ISBN 978-3-319-73207-7 (eBook) doi.org/10.1007/978-3-319-73207-7_9
1 citare, citat de (1):
1. Adini B, Singer SR, Ringel R, Dickmann P. Earlier detection of public health risks - Health policy lessons for better compliance with the International Health Regulations (IHR 2005): Insights from low-, mid- and high-income countries. *Health Policy*. 2019: S0168-8510(19)30157-5. (Current impact factor: 2.075).
2. Preda, M., Popa, MI., Mihai, MM., Șerbănescu, AA., Holban, A M. (2019). Natural Fibers in Beverages Packaging. In *Trends in Beverage Packaging* (pp. 409-424). Academic Press.
1 citare, citat de (1):
1. Vinod A, Siengchin S, Parameswaranpillai J. Renewable and Sustainable Biobased Materials: An Assessment on Biofibers, Biofilms, Biopolymers and Biocomposites. *Journal of Cleaner Production*. 2020:120978. (Current impact factor:6.39)